

AD \_\_\_\_\_

CONTRACT NUMBER: DAMD17-94-C-4120

TITLE: Effect of a Soy Dietary Supplement on Menopausal Symptoms  
and Hormones in Women at High Risk of Breast Cancer

PRINCIPAL INVESTIGATOR: Margo N. Woods

CONTRACTING ORGANIZATION: Tufts University School of Medicine  
Boston, Massachusetts 02111

REPORT DATE: October 1995

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release;  
distribution unlimited

The views, opinions and/or findings contained in this report are  
those of the author(s) and should not be construed as an official  
Department of the Army position, policy or decision unless so  
designated by other documentation.

19951213 031

DTIC QUALITY INSPECTED 1

REPORT DOCUMENTATION PAGE			Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.				
1. AGENCY USE ONLY (Leave blank)	2. REPORT DATE October 1995	3. REPORT TYPE AND DATES COVERED Annual 30 Sep 94 - 29 Sep 95		
4. TITLE AND SUBTITLE Effect of a Soy Dietary Supplement on Menopausal Symptoms and Hormones in Women at High Risk of Breast Cancer		5. FUNDING NUMBERS DAMD17-94-C-4120		
6. AUTHOR(S) Margo N. Woods				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Tufts University School of Medicine Boston, Massachusetts 02111		8. PERFORMING ORGANIZATION REPORT NUMBER		
9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012		10. SPONSORING/MONITORING AGENCY REPORT NUMBER		
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION/AVAILABILITY STATEMENT  Approved for public release; distribution unlimited		12b. DISTRIBUTION CODE		
13. ABSTRACT (Maximum 200 words)  Hormone replacement therapy (HRT) is being sought by 30-40% of postmenopausal women (1). Recent studies suggest that HRT should not be used by women with breast cancer or by women at increased risk for the disease since HRT increases breast cancer risk in such women by 1.5 to 3.4 fold (2-6). Currently, no safe alternative to HRT is available to treat menopausal symptoms in these women.  Our research proposal will investigate the efficacy of an alternative treatment for menopausal symptoms using a soy dietary supplement bar containing high levels of phytoestrogens. Phytoestrogens, genistein and diadzein, have recently been reported to have weak estrogen-like properties and have demonstrated binding to estrogen receptors (7-8). The low levels of reported menopausal symptoms of hot flashes and night sweats in Japanese postmenopausal women as well as the lower risk of breast cancer in Japanese women have been suggested to be due to the high consumption of phytoestrogens in soy products in this population (9a).  Identifying a substitute for HRT that alleviated the hot flashes of menopausal women but did not carry an increased risk for breast cancer would be of important clinical significance to women at increased risk for breast cancer.				
14. SUBJECT TERMS  breast cancer - hormones - menopausal symptoms - phytoestrogens - soy		15. NUMBER OF PAGES 166		
		16. PRICE CODE		
17. SECURITY CLASSIFICATION OF REPORT  Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE  Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT  Unclassified	20. LIMITATION OF ABSTRACT  Unlimited	

## GENERAL INSTRUCTIONS FOR COMPLETING SF 298

The Report Documentation Page (RDP) is used in announcing and cataloging reports. It is important that this information be consistent with the rest of the report, particularly the cover and title page. Instructions for filling in each block of the form follow. It is important to *stay within the lines* to meet optical scanning requirements.

**Block 1. Agency Use Only (Leave blank).**

**Block 2. Report Date.** Full publication date including day, month, and year, if available (e.g. 1 Jan 88). Must cite at least the year.

**Block 3. Type of Report and Dates Covered.** State whether report is interim, final, etc. If applicable, enter inclusive report dates (e.g. 10 Jun 87 - 30 Jun 88).

**Block 4. Title and Subtitle.** A title is taken from the part of the report that provides the most meaningful and complete information. When a report is prepared in more than one volume, repeat the primary title, add volume number, and include subtitle for the specific volume. On classified documents enter the title classification in parentheses.

**Block 5. Funding Numbers.** To include contract and grant numbers; may include program element number(s), project number(s), task number(s), and work unit number(s). Use the following labels:

<b>C</b> - Contract	<b>PR</b> - Project
<b>G</b> - Grant	<b>TA</b> - Task
<b>PE</b> - Program Element	<b>WU</b> - Work Unit Accession No.

**Block 6. Author(s).** Name(s) of person(s) responsible for writing the report, performing the research, or credited with the content of the report. If editor or compiler, this should follow the name(s).

**Block 7. Performing Organization Name(s) and Address(es).** Self-explanatory.

**Block 8. Performing Organization Report Number.** Enter the unique alphanumeric report number(s) assigned by the organization performing the report.

**Block 9. Sponsoring/Monitoring Agency Name(s) and Address(es).** Self-explanatory.

**Block 10. Sponsoring/Monitoring Agency Report Number.** (If known)

**Block 11. Supplementary Notes.** Enter information not included elsewhere such as: Prepared in cooperation with...; Trans. of...; To be published in.... When a report is revised, include a statement whether the new report supersedes or supplements the older report.

**Block 12a. Distribution/Availability Statement.** Denotes public availability or limitations. Cite any availability to the public. Enter additional limitations or special markings in all capitals (e.g. NOFORN, REL, ITAR).

**DOD** - See DoDD 5230.24, "Distribution Statements on Technical Documents."

**DOE** - See authorities.

**NASA** - See Handbook NHB 2200.2.

**NTIS** - Leave blank.

**Block 12b. Distribution Code.**

**DOD** - Leave blank.

**DOE** - Enter DOE distribution categories from the Standard Distribution for Unclassified Scientific and Technical Reports.

**NASA** - Leave blank.

**NTIS** - Leave blank.

**Block 13. Abstract.** Include a brief (*Maximum 200 words*) factual summary of the most significant information contained in the report.

**Block 14. Subject Terms.** Keywords or phrases identifying major subjects in the report.

**Block 15. Number of Pages.** Enter the total number of pages.

**Block 16. Price Code.** Enter appropriate price code (*NTIS only*).

**Blocks 17. - 19. Security Classifications.** Self-explanatory. Enter U.S. Security Classification in accordance with U.S. Security Regulations (i.e., UNCLASSIFIED). If form contains classified information, stamp classification on the top and bottom of the page.

**Block 20. Limitation of Abstract.** This block must be completed to assign a limitation to the abstract. Enter either UL (unlimited) or SAR (same as report). An entry in this block is necessary if the abstract is to be limited. If blank, the abstract is assumed to be unlimited.

## FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the US Army.

Where copyrighted material is quoted, permission has been obtained to use such material.

Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Resources, National Research Council (NIH Publication No. 86-23, Revised 1985).

✓ For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories. ....

Accession For	
NTIS CRA&I	<input checked="checked" type="checkbox"/>
DTIC TAB	<input type="checkbox"/>
Unannounced	<input type="checkbox"/>
Justification	
By	
Distribution /	
Availability Codes	
Dist	Avail and/or Special
A-1	

*Harry N. W. W. W.* *October 25, 1995*  
PI - Signature Date

4. Table of Contents	Page
1. Front Cover	1
2. SF 298 Report Documentation Page	2
3. Foreward	3
4. Table of Contents	4
5. Introduction: Background, Purpose, Design and Recruitment	5
6. Body: Statement of Work/Progress Report	13
7. Conclusions: Plans for the coming year	21
8. References:	22
9. Appendix:	25
A. Menopausal Questionnaire	
B. Medical History Form	
C. Study Log (of menopausal symptoms)	
D. Seven Day Daily Symptoms Diary	
E. Food Record Booklet	
F. Manual of Operations (MOOP)	
G. Consent Form-Tufts	
H. Consent Form-Sloan Kettering	
I. Recruitment Material-Tufts	
J. Recruitment Material-Sloan Kettering	
K. Protein Technology, International (PTI) Supplement Bar Nutrient Content	

## 5. INTRODUCTION: BACKGROUND /PURPOSE/DESIGN/RECRUITMENT

### A. Introduction

#### *Menopause, Hormone Replacement Therapy and Breast Cancer*

The use of hormone replacement therapy (HRT) has increased in recent years and presently 30% of American women in early menopause receive HRT (1). While there are reported benefits of HRT on cardiovascular disease, osteoporosis, and menopausal symptoms, there are concerns about the effect of HRT on increasing the risk of breast cancer (2-6). Two recent meta-analyses (13,14) reported an increased risk of breast cancer with estradiol products and increased risk with longer duration of use (13,15). The current research does not allow clear interpretation of the data since the dose and type of drug varied from study to study. Steinberg et al. found in their meta analysis that women on HRT with a family history of breast cancer showed an increased breast cancer risk of 3.4 (13). Colditz, et al., in the Nurses Health Study reported an increased risk of breast cancer in women currently taking estrogens but no effect in those who took them in the past (16). The current recommendations are to avoid HRT in menopausal women who are at increased risk for the breast cancer, leaving these women without a safe alternative treatment for relief of menopausal symptoms.

#### *Serum Hormones at Menopause and Menopausal Symptoms*

During the perimenopausal phase some women experience irregular menstrual cycles (17,18) and fluctuation in hormone levels. Estradiol excretion from the ovaries is decreased, which triggers a marked increase in FSH and to a lesser extent LH. Increases of these gonadotropins from the hypothalamus-pituitary axis is a standard response in the female to low levels of estrogen to induce more estrogen production in the ovaries. However, at menopause the ovaries are unable to respond to this trigger. Levels of FSH that are consistently elevated ( $>25$  IU/liter) or FSH/LH ratio  $> 1$  are often used to define menopause. These gonadotrophins are useful markers of relative post-menopausal estrogenation (19). At menopause, estradiol and estrone are approximately  $1/3$  to  $1/2$  lower than baseline levels normally found in the follicular phase of the cycle, in premenopausal women, and show no rise during the month when tested by multiple serum sampling.

The potential sources of estrogen compounds in menopausal women include: 1) residual excretion of estrogen from the ovaries (20) plus ovarian excretion of at least 30% of the serum androstenedione, (a precursor of estrone), and 2) androgens, produced in the adrenals and secreted into the blood (21-24), which can be converted in the adipose tissue to estrogens by the enzyme, steroid aromatase (22,25,26). In addition, alcohol intake can further stimulate the conversion of androstenedione to estrogen via induction of the steroid aromatase enzyme (27-29).

Commonly held beliefs concerning symptomatology of menopause are currently being questioned (30-32) and many of the affective disorders ascribed to menopause are found to be based on inadequate data (33). Menopausal symptoms which are cited as most problematic are "hot flashes" and "night sweats" and occur in 50-85% of women (34,35). The study by Avis, et al (37) provides a cross cultural reporting of symptoms and indicates that Canadian and American women report hot flashes and night sweats at a rate of 46 and 43%, respectively, while only 17% of Japanese women report these symptoms in natural menopause. Locke (37) reported that 9.7% of Japanese women had hot flashes and 3.6% had night sweats; in contrast, 30.9% of Canadian women reported hot flashes and 19.8% night sweats. One study investigating menopausal symptoms reported that these symptoms are inversely related to serum estrogen levels (11); those women with lower serum estrogens had higher reported symptoms. This appears to contradict the data available on Japanese women who have lower levels of estrogens and report fewer of these symptoms (37). Differences in cultural expectations have been cited as one explanation for these variations in menopausal symptoms, but there are also other possible reasons which include dietary patterns. Japanese women consume high levels of soy products which contain phytoestrogens and this might impact their hormonal status and symptomatology. The possibility that soy products can influence the sex hormone metabolism of Japanese women is of interest since they report lower menopausal symptoms and have decreased estrogenation.

### *Phytoestrogens*

Phytoestrogens are estrogen-like compounds found in plant products and high fiber foods such as whole grains, seeds, and legumes (especially soy) and are known to have both estrogenic and anti-estrogenic properties. The two most prevalent phytoestrogens are genistein and daidzein and they appear in high concentrations in soy products. High intake of soy products has been suggested to be the contributing factor in the low incidence of breast and prostate cancer observed in Japanese women and men respectively (38). Intake of dietary soy has been shown to be inversely associated with breast cancer risk in Singapore (39). In addition to phytoestrogens (isoflavones), two other categories of compounds (flavones and lignans) have also been investigated for their estrogenic properties. Adlercreutz, et al. (40-45) have published a series of papers on populations eating diets with different intakes of fiber and compared their urinary phytoestrogens and lignan concentrations. The findings show that strict vegetarians (macrobiotics) have elevated levels of urinary phytoestrogens and lignans compared to omnivores. Japanese women had elevated urinary phytoestrogens compared to omnivores but not significantly higher lignans. Based on these studies, Adlercreutz et al. concluded that the concentrations of anti-estrogenic plant compounds in the urine are correlated with plant food consumption (40,46). They further suggested that isoflavanoids stimulate the synthesis of sex hormone binding globulin (SHBG) in the liver (47,48). Support for this comes from studies on urinary levels of phytoestrogens and lignans and plasma concentrations of SHBG in Finnish omnivores and vegetarian females (47,48). The elevated SHBG would result in a decrease in the percent of free estradiol available to bind at estrogen receptor sites. Phytoestrogens have weak estrogenic activity, as demonstrated by binding to the type I estrogen receptor (7,8), and also anti-estrogenic activity (9). The anti-estrogen properties are related to the ability of phytoestrogens to compete with estradiol, estrone and estriol for the nuclear type II receptor (9).

The estrogenic activity is determined by the affinity for the estrogen receptor and the phytoestrogens are one fiftieth to one two hundredth of that of estradiol (7). The ability of phytoestrogens to bind estrogen receptors (7,8) increase SHBG and exhibit estrogenic activity in rats as determined by vaginal cytology (49) indicates the potential of the phytoestrogens to substitute in selective ways for endogenous or exogenous estrogens. Another possible role for the phytoestrogens may be as an alternative to exogenous hormones for decreasing menopausal symptoms. This area deserves serious consideration given the risk associated with administration of exogenous estrogen in women at increased risk of breast cancer. In addition, there are also reports on the possible anticarcinogenic effects of the phytoestrogens (50,51,52).

This research seeks to find an alternative to HRT for treatment of menopausal symptoms in women at increased risk for breast cancer. Our proposed study will use women at high risk for breast cancer to investigate the effect of a dietary supplement made from soy on the frequency and intensity of menopausal symptoms of hot flashes and night sweats. We will also determine whether menopausal symptoms are correlated with endogenous estrogen hormones ( $E_1$ ,  $E_2$ ,  $E_1SO_4$ , FSH and androstenedione). Urinary phytoestrogens will be measured to document any correlation between phytoestrogens and symptoms and serum hormone levels, and to determine compliance with the intervention.

## **B. Hypothesis**

The use of a soy dietary supplement bar in women at increased risk for breast cancer and reporting high menopausal symptomatology will result in a decrease in symptoms as well as alterations in endogenous hormone levels.

## **C. Specific Aims**

1. Recruit 100 high risk menopausal women for the study who are experiencing frequent and consistent menopausal symptoms of hot flashes ( $\geq 5$  per daytime hours) and/or night sweats ( $\geq 5$  per week) to participate in an intervention study. Recruit 100 high risk menopausal women without symptoms who will act as a control group in which only baseline data will be collected.
2. Use a randomized, cross-over study design, in which high risk women with high menopausal symptoms will be given a soy dietary supplement bar or a placebo bar for 3 months, with a wash out period of 1 month, followed by the alternative dietary intervention.
3. Collect data on menopausal symptoms using a daily symptoms diary for the duration of the intervention study.
4. Collect blood samples for determination of sex hormone levels for two days at baseline, after three months of soy supplementation and after three months of placebo.



5. Collect a 24 hour urine sample for determination of phytoestrogens at baseline, after three months of soy supplementation and after three months of placebo.
6. Collect a food frequency questionnaire at baseline on all participants and 3-Day Food Records from the Intervention Group at baseline and at the end of each study phase, concurrent with the blood and urine collections.

## D. Methods

### 1. Design and Flow Chart

This proposed dietary intervention study will use a randomized cross-over design (outlined below) to determine the effect of a soy dietary supplement bar on endogenous hormones and menopausal symptoms. (See Figure 1). A control group with few or no menopausal symptoms will be used to collect baseline data only.

**FIGURE 1**  
Study Design and Parameters

	Baseline	Phase I	Phase II	Phase III
Time (months)		3	1	3
Intervention Group (n=100)				
	I (50)	Supplement	Placebo	Placebo
	I (50)	Placebo	Placebo	Supplement
Controls (n=100)	C	-	-	-
Determinations				
Hormones	I,C	I	-	I
Dietary Data	I,C	I	-	I
Urinary Phytoestrogens	I,C	I	-	I
Menopausal symptoms	I,C	I	-	I

NOTE: I = Intervention; C = Controls

A cross over design is important in order to remove the effect of time on the menopausal symptoms and to determine the placebo effect on the subjective symptoms of menopause.

Menopausal symptoms have been reported to be present for as little as a few months and up to 5-6 years (18,72). Physical activity, life events, and weight changes have been reported to influence menopausal symptoms (17,73-75) and will also be monitored throughout the study.

## **2. Eligibility Criteria/Exclusion Criteria of Participants**


Women, ages 48-58, at high risk for breast cancer, who are post-menopausal (no periods for at least one year) are eligible for the study (Figure 2). High risk is defined as having one or more of the following characteristics: 1) mother or sister with breast cancer, 2) two or more benign breast biopsies, and 3) one breast biopsy with diagnosis of proliferative breast disease. Menopausal symptoms will be ascertained using a "Menopausal Questionnaire" and those who report  $\geq 5$  hot flashes during daytime hours and/or  $\geq 5$  night sweats per week will be eligible for the intervention arm of the study. Women with  $\leq 2$  hot flashes during daytime hours or  $\leq 1$  night sweats per week will be eligible for the control group. Women recruited must be within 90-120% of ideal body weight.

An extensive medical history will be taken and those women with the following characteristics will be excluded: surgical menopause (no intact ovaries); currently on hormone replacement therapy (HRT); previous use of HRT within the last 6 months; previous breast cancer; history of frequent use of antibiotics ( $>2$  times over the last 3 years); and high intake ( $> 25$  gm/day) of soy products.

**FIGURE 2**

Study Design: Randomized Cross-Over Design for a Soy Dietary Supplement Bar

Recruit: Women at high risk for breast cancer  
Menopausal: ( $\geq 1$  year since last menstrual cycle) Age: 48-58 years



### 3. Recruitment

Two sites will be used to recruit the high risk women: Tufts New England Medical Center-Breast Health Clinic in Boston and Memorial Sloan Kettering Cancer Center- Special Surveillance Breast Program in New York City. Each site will recruit 50 high risk women with high menopausal symptomatology and 50 high risk women with low menopausal symptomatology.

a. Tufts New England Medical Center (T-NEMC)/ Breast Health Clinic

Since its formation in 1981, the New England Medical Center Breast Health Center (BHC) has been a multidisciplinary out-patient unit dedicated to the diagnosis and treatment of breast disease. The center is currently directed by Dr. Thomas Smith and is located on the 6th Floor of the Biewend Medical Building - the main New England Medical Center office building.

Recruitment for this study will be conducted via letters to current age appropriate, high risk patients at the BHC. There are currently 5,500 patient visits annually, with 3,000 registered patients and 1,200 new patients added each year. Twenty to twenty-five percent of these patients are in the appropriate age range of 48-58 years of age and 50% are estimated to be at high risk due to family history or benign biopsy. If additional participants are needed, a recruitment strategy would include advertisement through the NEMC newsletters and to the general population via the two large Boston daily newspapers.

Estimates on prevalence of menopausal symptoms are based on a number of reports on U.S. menopausal women (18,33-35,37). The data from the Massachusetts Women's Health Study, which is the largest epidemiological study of the health of middle-aged women, included over 8,000 women and was started in 1982 with data collection continuing. Results from this study indicate that 35% report having hot flashes and 30% report trouble sleeping with 11% reporting night sweats (37). This data does not quantify the frequency of these symptoms, and it is estimated that 15-20% of age-eligible, high risk women would have the intensity of symptoms needed to make them eligible for this study:  $\geq 5$  hot flashes per daytime or  $\geq 5$  night sweats per week (18). Of those eligible, we would expect to be able to recruit and retain approximately 30% into the study. High risk women with low levels of symptoms of menopause (defined above) will be eligible for the control group (N=50).

Using these assumptions, we estimate that we will be able to recruit 15 age eligible, high risk, symptom eligible women from our current clinic rosters. An additional 12 women can be recruited each year from newly enrolled patients. The accrual of subjects will continue over 2 ½ years. This predicts that almost all the Boston study population (n= 50) could be recruited from our BHC. A large cohort of low-symptom control women is also available. Included in our proposal is the enthusiastic support letter of the director of the BHC. A trained recruiter will be available at the clinic site 3 half-days a week (which represents the scheduled clinic times). Dr. Susan Sajer, a staff oncologist and member of the BHC, will be involved in setting the clinic protocol for recruitment within the BHC and OB/GYN clinics. To enhance accrual, we plan to use strategies which have been proven effective in the recruitment of women to the NSABP breast cancer prevention trial, Protocol P-1 (Tamoxifen Study). Specifically, this includes the use of our Tufts-NEMC ECOG/NSABP network of physicians, informational sessions for interested women and advertisements. We currently have a designated Cancer Prevention nurse who is familiar with our patient population, and she has successfully used the above strategies for patient recruitment.

b. Recruitment of study subjects from the Special Surveillance Breast Program of Memorial Sloan Kettering Cancer Center

Two sources of patients are available for recruitment to the study from the newly opened Breast Diagnostic and Treatment Center of Memorial Sloan Kettering Cancer Center: women attending the Special Surveillance Breast Program and women receiving continuing care after surgery for a benign breast condition by one of the six breast specialists who are members of the Breast Service, Department of Surgery.

More than 1300 women are currently registered with the Special Surveillance Breast Program (SSBP), a breast cancer screening program specifically designed to meet the needs of women at elevated risk of developing breast cancer. The level of increased risk is estimated by the extent of family history, the ages at diagnosis of relatives, and the histology of prior benign breast surgery. As of October 1993 approximately 300 women are between the ages of 48 and 58, the target age group for the proposed study. If 20% of these women report severe menopausal symptoms and 50% agree to participate in the study, 30 women from the currently enrolled high risk patients would be recruited and retained. The accrual of subjects will continue over 2 ½ years. An average of 25 new patients have been enrolling in the program each month during 1993, potentially providing 5 to 10 additional study subjects annually from the SSBP. Women involved in our center have been very motivated and previous experience suggests that projected enrollment of 50% is reasonable. Women who are at high risk but with low levels of menopausal symptoms are readily available for the baseline control group (n=50).

Approximately 2,500 women are surgically treated for a benign breast condition by one of the six members of the Breast Service. More than 50% of these patients are between the ages of 40 and 60 with an estimated 600 postmenopausal women available for potential recruitment to the study. If severe menopausal symptoms are reported by 20% and 50% of those who are invited to participate are recruited, the required 50 study subjects could be readily recruited.

The Study Coordinator will have the responsibility of recruiting appropriate SSBP patients to the study. She will attend each session of the SSBP to review the medical records of all patients scheduled for reexamination; the baseline history of all newly enrolled patients will also be reviewed. Participation in this study will be offered to all currently enrolled women who meet the eligibility criteria at their first scheduled examination after initiation of recruitment. In addition, all new patients will be evaluated for eligibility at the time of first examination; if appropriate, study participation will be offered at that time. Women who do not schedule reexamination appointments at recommended intervals are contacted by phone and encouraged to return to the clinic. At this time all eligible women will be informed about the study and be given the opportunity to participate at the time of their follow-up examination. Once enrolled in the intervention trial, the Project Coordinator will have the responsibility of explaining the study goals, obtaining informed consent, collecting baseline and follow-up data, arranging for collection of bloods and urine specimens, instructing patients on dietary component of the study, and providing liaison with other services available at Memorial Sloan Kettering for women at high risk of breast cancer such as genetic counseling, nutrition counseling, and psychiatry.

## **6. BODY: STATEMENT OF WORK/PROGRESS REPORT**

The Effect of A Soy Dietary Supplement on Hormone Levels and Menopausal Symptoms in Women at Increased Risk for Breast Cancer

Task 1, Preparation to start study, Months 1-4:

- a. Study questionnaires will be developed, tested and printed (screening, menopausal symptoms, medical history, food records).
- b. Study recruiters will be trained.
- c. Data entry forms will be developed.
- d. Recruitment materials will be developed.
- e. Study protocols will be written

Task 2, Recruit subjects and begin study, Months 5-40:

- a. Rolling recruitment will take place from, Months 5-35:
  - 1. Letters will be sent to age eligible patients from clinic.
  - 2. Advertisements will be placed in newspapers as needed.
- b. Subjects will enter and complete study, Months 8-42:
  - 1. Study data will be collected and entered.
  - 2. Serum and urine samples will be collected, processed and analyzed.
  - 3. Dietary data will be collected and entered.

Task 3, Conclusion of Study, Months 42-48:

- a. Laboratory studies will be completed.
- b. Statistical analyses will be performed.
- c. Final report will be written.

## Progress Report/Work Accomplished

After receiving notification of funding for the study, Ann LaBrode was appointed study coordinator and started to work with Drs. Woods and Senie to develop the study protocol, Manual of Operations (MOOP) and study instruments. Dr. Senie also worked with staff at her site to develop the randomization scheme and the study data entry forms using the Paradox software program.

### A. Development of Study Materials:

1. Menopausal Questionnaire: Working Dr. Kronenberg we developed a questionnaire on menopause that was tested in our clinic. It provides information on the quality of the menopausal experience and also quantifies some specific indicators. A copy of the questionnaire appears in the Appendix (Item A).
2. Medical History Form: Our standard medical history form was reviewed and revised in order to take advantage of data that is collected at the Mt. Sinai Special Surveillance Breast Program and minimize the duplication of data collection. The final form is shown in the Appendix (Item B).
3. Menopausal Symptoms Collection Instruments: Two separate instruments were developed to collect data on menopausal symptoms from the women. One is identified as the Study Log and collects data on the consumption of the dietary bars plus the number of hot flashes during waking and sleeping hours each day with each week (Sunday-Saturday) on one page with space left for notes on illness, other medications, travel, etc. that took place during the week. These factors might have an effect on reporting of symptoms or on the symptoms themselves and tracking such events may be useful in identifying confounders. A definition of hot flash is also given. This instrument is used during recruitment to identify women for the study and enroll them in the control of intervention group. It is used to verify their subjective opinion on the number of hot flashes they experience per day.

The second instrument that was developed was the "Seven Day Daily Symptoms Diary" which requests that the participant record the time of day and intensity of the hot flash, each day for seven consecutive days during each phase of the study. This is a more detailed record of symptoms and requests documentation of each event as it happens. It will be used as the primary data source for the evaluation of the effect of soy versus a placebo bar on frequency and intensity of menopausal symptoms. These instruments are shown in the Appendix (Items C and D).

4. Food Record Booklet: A booklet was developed for the participants to record their food intake for 3 days. It also contains instructions on how to record this information with examples and prompts. This instrument is in the Appendix (Item E).
5. Manual of Operations (MOOP): Because the study was being collected at two sites, it was

important to describe each procedure in detail to facilitate standardized procedures at each site. To accomplish this a manual of operations was developed in which forms and procedures are outlined and detailed. This process is detailed and time consuming but necessary considering the different types of sites involved in the study. The MOOP is included in the Appendix (Item F). The MOOP is constantly updated and clarified as issues arise and both sites are given updated versions to maintain standard procedures. In general, pages may be substituted for earlier versions and all pages are dated. An important part of the MOOP is the data entry forms that have been developed for study data that are also present on disc, on the computers at each site. This document is the best reference for protocol questions that might arise at each site.

## **B. Recruitment Activities**

1. Human Study Forms: Final Human Consent Forms for signature by the participants were developed and reviewed at each of the study sites. Some minor changes and clarifications were requested after the study was reviewed following the funding of the project. The current consent forms from each site are included in the Appendix (Items G and H).
2. Recruitment Material:
  - a.. Tufts University School of Medicine  
The Boston site developed a one page recruitment flyer to be used at the Tufts-New England Medical Center Breast Health Clinic waiting rooms. Using mailing list from the Breast Health Clinic, women in the study age range were mailed material explaining the purpose and requirements of the study. Presentations on the research that supported the study goals were made by Dr. Woods to the staff at the clinic and the department of OB/GYN. Recruitment material is located in the Appendix (Items I and J).
  - b. Memorial Sloan-Kettering-Special Surveillance Breast Program  
All the women in the Special Surveillance Breast Program are at high risk for breast cancer and therefore are an excellent group from which to recruit. Women in the appropriate age range were identified and letters of information were sent to those who were scheduled for a clinic visit within the next two months. All women in the program are seen every six months. A study coordinator was available to screen women who called the study number or who agreed to be seen at the time of their regular clinic visit.
3. Recruitment Sites:
  - a.. Tufts University School of Medicine  
Four months after the funding of the program we had materials and advertisements available at the Tufts-New England Medical Center Breast Health Clinic. We had met with the clinic staff, presented our study rationale and design and provided them with the recruitment material for their review. Our co-investigator, Dr. Susan Sajer, who worked at the clinic had already reviewed the material. Samples of the soy bar were also provided to the physicians.



We have made contact with suburban hospitals to make presentations to their staff involved in breast care and OB/GYN, to encourage them to refer patients to our study. Study materials are available in the suburban clinics and offices. We have contacted three suburban hospitals and are planning to further develop this strategy to other small community hospitals. At the same time we are increasing our interaction with the staff at Tufts-New England Medical Center.

Six months into the study we mailed letters to age appropriate patients listed with the NEMCH Breast Health Clinic as cited above.

b.) Memorial Sloan-Kettering-Special Surveillance Breast Program

After receiving approval with outstanding merit from the Protocol Evaluation Committee of the Memorial Sloan Kettering Research Council, the study protocol was submitted to the Institutional Review Board and was approved at the meeting held on June 13, 1995. Copies of the study (#95-39) consent forms are enclosed.

During the past several months the procedures conducted at Memorial Sloan Kettering, in addition to the collaborative activities with Margo Woods and Ann LaBrode, have addressed identification of the population to be recruited to the study and arrangements for handling data and specimen collection.

The extensive files of the Special Surveillance Breast Program were searched for young women meeting the study criteria for recruitment including current age and level of risk of breast cancer. The date of last examination and subsequent appointment date were recorded. A letter of introduction was drafted to be sent to women three weeks prior to scheduled appointment date. The screening questionnaire previously developed is used at the time of follow-up phone call within the week prior to the scheduled visit. This sequence has worked well to identify women who are interested in joining the study and who meet the recruitment criteria. In addition, the project director will be advised of any new patients being examined for the first time by Drs. Heerdt or Van Zee of the Special Surveillance Breast Program, who meet the study criteria. These women will be invited to join the **Soy Study** at that time if, on review of the screening questionnaire, they meet all requirements for enrollment in the study.

After signing the appropriate consent forms, women are interviewed and complete data collection instruments at the time of enrollment at the Memorial 64th Street Breast Cancer. Blood specimens are drawn at the Breast Cancer and are carried to the Breast Cancer Laboratory in the Rockefeller Building for processing and freezing. The study subjects return 3 to 7 days later bring with them a sample of first morning urine in the container previously provided. A second blood specimen is collected. Methods for collecting the three day food records are explained during the second visit. Women with extensive symptomatology are advised of their recruitment to the intervention component of the project and are provided in the dietary supplement bars for two weeks. Phone contact is maintained weekly with subjects enrolled in the intervention and additional packages are sent by Fedex

each two weeks.

4. Current Recruitment Status:

a.. Tufts School of Medicine

We began recruiting for the study February 1995, 5 months into the study, however, due to problems with the soy dietary bar we had to put these activities on hold until these issues were resolved. See the section below for details. As of August 1995 we had received soy dietary bars and placebos that met specifications and could proceed with recruitment. We currently have five women in the study consuming the dietary bars and following the study protocol. Our original recruitment plan has not been able to proceed which would have recruited 1.4 women per month for 7 months of the first year or 10 women at the end of year one. An equal number of women with low level of symptoms would also be recruited to collected baseline data only. We have not been actively recruiting this population because we are more confident in obtaining these women and have put our effort into resolving the issue of acceptability of the dietary soy bar.

b. Memorial Sloan-Kettering-Special Surveillance Breast Program

Four women have been recruited from the Special Surveillance Breast Program into the Menopausal Symptoms Study and are currently in Phase I. Letters continue to be sent out to clinic patients prior to their scheduled visits. In addition, 250 new women are added to the clinic roster each year and therefore these new women are also contacted.

5. Projected Recruitment Plans

a.. Tufts School of Medicine

The original recruitment plan was to recruit 100 women in 35 months while the adjusted plan is to recruit 95 women in 30 months or 3 women per month. More accurately this entails recruiting 1.5 women into the high symptom-dietary intervention group per month and 1.7 women per month into the control group for just baseline data. With our current recruitment plan of contacts in the suburban hospitals we believe we can meet this slightly accelerated plan. In addition we have also begun general advertising in the Boston Globe and suburban newspapers. We currently have over 25 women going through the screening process for recruitment into the study from responses to the newspaper advertisements alone.

Community based recruitment efforts are currently underway and include participation in community outreach programs, increased media attention, contact with local Breast Cancer and Public Health organizations, research seminars, and participation in local Health Fairs. These efforts are described below in more detail.

*Community Outreach Programs:* Most of the suburban hospitals in the greater Boston area

have recently initiated broad based community outreach programs. These programs include health awareness programs for the general public, newsletters and extensive support networks for breast cancer patients and families. We have contacted a number of these community outreach programs and are coordinating our recruitment efforts with these programs. Presentations have been made at Emerson Hospital in Concord, MA and at a Breast Cancer Awareness Program sponsored by The Cancer Care Center at Southwood Community Hospital in Norfolk, MA.

*Increased Media Attention:* Articles about the study have appeared in the Tufts University Diet and Nutrition Letter (February 1995) and in the Tufts University School of Medicine Deans Rounds (Spring 1995). We are currently preparing articles for release in local newspapers and have contacted television networks for spots on local news broadcasts. Segments about our research have been aired on Channel 25 - The News at 10:00 and arrangements are currently being made with other local stations. Press releases about the study have been sent to local radio stations requesting that public service announcements be made about the study. Advertisements have now been placed in local newspapers, and notices are currently appearing in the Health/Science section of the Boston Globe. These efforts will continue.

*Breast Cancer and Public Health Organizations:* Local public health and breast cancer organizations have been contacted and informed about our recruitment efforts. A presentation about the study was given at the Mass Department of Public Health Women's Health Breakfast Series and the study was highlighted in the last newsletter from the Department of Public Health. We are currently working with The Massachusetts Breast Cancer Coalition and local Breast Cancer Support organizations since first degree relatives of breast cancer patients are part of the population being recruited for this study. Study representatives have attended local Breast Cancer Fundraising Efforts including the Walk for Breast Cancer held this fall in Boston. Study representatives will continue to be visible at local Breast Cancer events.

*Research Seminars and Presentations:* Several research seminars and presentations have been made to inform the medical and research community about our study. We are currently contacting local business's and health care organizations to organize future talks. A research seminar has been scheduled for November 7, 1995 at the United States Army Research and Development Command at Natick, Massachusetts. It is our hope that local researchers will be instrumental in passing information about the study to friends, families and the general public.

*Health Fairs:* We are planning to attend local Health Fairs and have designed materials to be set up and distributed at a booth. We are contacting the organizers of these events to obtain dates and reserve space.

- b. Memorial Sloan-Kettering Cancer Center- Special Surveillance Breast Program

The current recruitment plan appears to be working and response has been adequate. Personnel hired and trained this summer have returned to graduate studies and a new recruiter is being trained to continue the study screening, recruitment and study protocol. Dr. Woods and Ms. LaBrode will visit the Memorial Sloan-Kettering in November to review protocols and quality control procedures and check for the consistency between the two sites.

### **C. Development of the Soy Dietary Supplement Bar**

Prior to the submission of the grant we had worked with Standard Hospital Supplies (SHS) to develop a soy dietary supplement bar that met the criteria for the study by containing 40 mg of phytoestrogens in two dietary bars which would be consumed each day. The development of the placebo bar was not complete but was considered by SHS to be a routine production issue in which casein protein would be substituted for the soy protein. SHS also discussed doing shelf life studies on the supplement bar.

With the funding of the grant we went forward our production plans and schedule to develop the soy dietary supplement bars. However, due to some delays in revising the consent forms the dietary bars were stored for two months in our unit prior to recruitment. During recruitment presentations we would bring the dietary bars so prospective participants could determine their acceptability. It was during this process we discovered that the bars changed drastically during storage and resulted in the consistency going from a soft nougat like texture to taffy to hardened taffy. This was an unacceptable product and all attention was given to the reformulation of the dietary supplement bar.

Evaluation of the problems and the possible solutions led us to contact Protein Technologies, International (PTI) as an alternate source of the soy dietary supplement bars. They already had a chocolate flavored bar that met our expectation of phytoestrogen content. A placebo had not been formulated or tested by them, however. After considerable discussion with both suppliers we decided to use PTI as the supplier.

PTI agreed to produce the product without the chocolate covering for our study and to package it to meet our requirements. They assured us that an acceptable and indistinguishable placebo could be produced within two months. We have now received tasty, soft and acceptable soy and placebo bars from PTI for the study with 4 month shelf-life studies indicating no deterioration in the quality of the placebo product. They had previously tested the 1 year shelf life of their soy dietary supplement bar. A production schedule has been worked out with PTI to assure an ongoing supply of soy and placebo bars for the duration of the study. The nutritional assessment of the soy and placebo dietary supplement bars is presented in the Appendix (Item K).

### **D. Labeling and Distribution of the Dietary Supplement Bars**

Supplement bars are delivered to the Tufts, Nutrition Unit where they are checked for quantity and quality. A labeling procedure has been developed for the study that is used to package the participant's supply of bars for Phase I and Phase III. This labeling and packaging is carried out by

a research associate who has access to the identification of the randomization code numbers for the participants (regarding which bar, soy or placebo, they are to receive for the Phase I and Phase III periods). No other study personnel has access to this information. This procedure has been used in the past in other studies using placebos and blinding of participants and study personnel. The bars are packaged for each individual randomized code and are ready to be supplied to either of the two sites as participants are randomized into the trial. The individual sites supply the participants with bars for only one phase at a time. At Memorial Sloan-Kettering, the bars may be mailed to the participants since most use public transportation to the clinic site and the bars may be too heavy. Subjects are asked to return any unused bars from each phase. An extra two week supply may be given to ensure availability in case the clinic visits are delayed at the end of each phase. All study personnel that are involved in recruiting or interaction with the participants in any way are blinded to the identification of the supplement bars which are indistinguishable in appearance.

#### **E. Data Collection**

1. Randomization procedures:  
See page 6 of the MOOP in the Appendix.
2. Data entry forms  
Programs have been written so that all data forms are entered on Paradox. Forms will be entered at each clinic side and standard data sets will be generated from all forms at each clinic. The data analysis will be conducted starting at the end of year 3.

#### **F. Training of Study Personnel**

Personnel at Memorial Sloan-Kettering have been trained by staff from Tufts and Dr. Senie. Certification procedures are in place for training of participants in the recording of the food record and the documentation of the returned record. In addition personnel have visited at Tufts to observe and practice the collection, storage and handling of blood and urine samples and training subjects on all the study instruments. Once a year visits between the two sites are being scheduled to maintain vigilance on quality control procedures. Previous experience with studies conducted at multiple sites has made us aware of the issues that need to be addressed.

## **7. CONCLUSIONS: PLANS FOR THE COMING YEAR**

The current data on phytoestrogens continues to look provocative regarding its potential as a modulator of endogenous estrogen status and an anticarcinogenic agent.

We have had two national medical news teams interview myself and my colleagues on our studies involving phytoestrogens. We have received numerous phone calls from across the country, however, recruiting for our study is limited to the Boston or NYC areas. We are pleased with the palatability of the dietary supplement bars and the efficient plan of the protocol. We expect to meet our recruitment schedule and obtain high quality data on menopausal symptoms, hormones and dietary intake for our data analysis.

Identifying a substitute for HRT that alleviated the hot flashes of menopausal women but did not carry an increased risk for breast cancer would be of clinical significance to women at increased risk for breast cancer. In addition, the study would supply data on the effect of phytoestrogens on endogenous hormone levels that might indicate their possible role in decreasing risk for breast cancer.

### J-3 BIBLIOGRAPHY

1. Harris RB, Laws A, Reddy FM, King A, Haskell WL: Are women using postmenopausal estrogens? A community survey. *Am J Public Health* 80:1266-68, 1990.
2. Wallach S, Henneman PH: Prolonged estrogen therapy in postmenopausal women. *JAMA* 171:1637-1642, 1959.
3. Kaufman DW, Miller DR, Rosenberg L. et al.: Noncontraceptive estrogen use and risk of breast cancer. *JAMA* 252:63-67, 1984.
4. Nomura AMY, Kolonel LN, Hirohata T, Lee J.: The association of replacement estrogens with breast cancer. *Int J Cancer* 37:49-53, 1986.
5. Brinton LA, Hoover R, Fraumeni JF, Jr.: Menopausal oestrogen and breast cancer risk: an expanded case-control study. *Br J Cancer* 54:825-32, 1986.
6. LaVecchia C, DeCarli A, Parazihni F, Gentile A, Liberati C, Franceschi S.: Noncontraceptive oestrogen and risk of breast cancer in women. *Int J Cancer* 38:853-858, 1986.
7. Shutt DA, and Cox RI.: Steroid and phytoestrogen binding to sheep uterine receptors. *J. Endocrinol* 52:310, 1922.
8. Tang BY, and Adams NR.: Effect of equol on oestrogen receptors and on synthesis of DNA and protein in the immature rat uterus. *J. Endocrinol* 85:291-297, 1980.
9. Adlercreutz H, Mousavi Y, Loukovaara M, Hamalainen E.: Lignans, isoflavones, sex hormone metabolism and breast cancer. In "The New Biology of Steroid Hormones" (In Press).
- 9a. Adlercreutz H, Gorbach S, Goldin B.: Dietary phyto-oestrogens and the menopause in Japan. *Lancet* 339:1233, 1992.
10. Shimizu H, Ross RK, Bernstein L, Pike MC, Henderson BE.: Serum estrogen levels in postmenopausal women: comparison of American white and Japanese in Japan. *Br J Cancer* 62:451-453, 1990.
11. Erlik Y, Meldrum DR, Judd HL.: Estrogen levels in postmenopausal women with hot flashes. *J Am Coll Obstet and Gyn.* 59:403-6, 1982.
12. Gavalier JS. Alcohol and Nutrition in postmenopausal woman.: *J Am Coll Nutr* 12:349-356, 1993.
13. Steinberg K, Thacker SB, Smith J et al.: A Meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. *JAMA* 265:1985-90, 1991.
14. DuPont WD, Page DL: Menopausal estrogen replacement and breast cancer. *Arch Int Med* 151:67-72, 1991.
15. Hulka BS.: Hormone-replacement therapy and risk of breast cancer. *CA* 40:289-96, 1990.
16. Colditz GA, Stampen MJ, Willet WC, Hennekens CH, Rosner B, Spiezer FE.: Perspective study of estrogen replacement therapy and risk of breast cancer in postmenopausal women. *JAMA* 264:264-53, 1990.
17. Longcope C, Franz C, Morreal C, Baker R, Johnston CC Jr.: Steroid and gonadotrophin levels in women during the peri-menopausal years. *Maturitas* 1986;9:189-196.
18. Feldman BM, Voda AM, Gronseth E.: The prevalence of hot flash and associated variables among perimenopausal women. *Res Nurs Health* 8:261-268, 1985.
19. Gavalier JS. Effects of moderate consumption of alcoholic beverages on endocrine function in postmenopausal women: bases for hypotheses. In Galanter M (ed): "Recent Developments in Alcoholism." New York: Plenum, pp 229-251, 1988.
20. Gavalier JS. Alcohol effects in postmenopausal women: alcohol and estrogens. In Mendelson J, Mello N (eds): "Diagnosis and Treatment of Alcoholism," 3rd ed. New York: McGraw Hill, pp 623-638, 1992.
21. Judd HL, Judd GE, Lucas WE, Yen SSC.: Endocrine function of the postmenopausal ovary: concentrations of androgens and estrogens in ovarian and peripheral vein blood. *J Clin Endocrinol Metab* 39:1020-1024, 1974.
22. Nordin BEC, Crilly RG, Marshall DH, Barkworth SA.: Oestrogen, the menopause and the adenopause. *J Endocrinol* 89:131-143, 1981.
23. Vermeulen A.: The hormonal activity of the postmenopausal ovary. *J Clin Endocrinol Metab* 42:247-253, 1976.
24. Chang RJ, Judd HL.: The ovary after menopause. *Clin Obstet Gynecol* 24:181-191, 1981.
25. Crilly RG, Marshall DH, Nordin BEC.: Adrenal androgens in postmenopausal osteoporosis. In Genazzani AR, Thijssen JHH, Siiteri PK (eds): "Adrenal Androgens." New York: Raven Press, pp 241-258, 1980.
26. Poortman J, Thijssen JHH, Schwartz F.: Adrenal androgen production and conversion to estrogens in normal postmenopausal women and in selected breast cancer patients. *J Clin Endocrinol Metab* 37:101-109, 1973.
27. Gordon GG, Altman K, Southren AL, Rubin E, Lieber CS.: Effect of alcohol (ethanol) administration on sex-hormone metabolism in normal men. *N Engl J Med* 295:793-797, 1976.
28. Gordon GG, Olivo J, Fereidoon F, Southren AL.: Conversion of androgens to estrogens in cirrhosis of the liver. *J Clin Endocrinol Metab* 40:1018-1026, 1975.
29. Longcope C, Kato T, Horton R. Conversion of blood androgens to oestrogen in normal adult men and women. *J Clin Invest* 48:2212-2201, 1969.
30. McKinley SM, Jeffreys M.: The menopausal syndrome. *Br J of Prev and Social Med* 28:108-115, 1974.
31. Greene JG.: A fact or analytic study of climacteric symptoms. *J of Psychosomatic Research* 40:425-30, 1976.
32. Greene JG, Cooke DJ.: Life stress and symptoms at the climacterium. *Br J of Psychiatry* 136:486-91, 1980.
33. Schmidt PJ, Rubinow DR.: Menopause-related affective disorders: A justification of further study. *Am J*

- Psychiatry 148:844-52, 1991.
34. Swartzman LC, Edelberg R, Kemmann E.: Impact of stress on objectivity recorded menopausal hot flashes and on flush report bias. *J Health Psychology* 9:529-45, 1990.
35. Kronenberg F, Downey JA.: Thermoregulatory physiology of menopausal hot flashes a review *Can J Physiol Pharmacol* 65:312-24, 1987.
36. Avis NE, Kaufert PA, McKinley SM, Vass K.: The evolution of menopausal symptoms. *Bailliere's Clin Endocrinol and Met* 7:17-32, 1993.
37. Lock M, Kaufert P, Gilbert P.: Cultural constructions of the menopausal syndrome. The Japanese case. *Maturitas* 10:317-332, 1988.
38. Adlercreutz H, Honjo H, Higashi A, et al.: Urinary excretion of lignans and isoflavanoid phytoestrogens in Japanese men and women consuming a traditional Japanese diet. *Am J Clin Nutr* 54:1093-1100, 1991.
39. Penz Lee H, Gourley L, Dryfy SW et al.: Risk factors for breast cancer by age and menopausal status:a case-control study in Singapore. *Cancer Causes and Control* 3:313-322, 1992.
40. Adlercreutz H, Hockerstedt K, Bannwart C.: Effect of dietary components including lignans and phytoestrogens on enterohepatic circulation and liver metabolism of estrogens and sex hormone binding globulin. *J Steroid Biochem* 27:1135, 1987.
41. Adlercreutz H, Fotsis T, Bannwart C.: *J Steroid Biochem* 24:289, 1980.
42. Adlercreutz H, Fotsis T, Heikkinen R, Dwyer J, Goldin BR, Gorbach SL, Woods MN.: Excretion of the lignans, enterolactone and enterodiol, and of equol in omnivorous and vegetarian postmenopausal women and in breast cancer. *Lancet* 2:1295-1299, 1982.
43. Adlercreutz H, Fotsis T, Heikkinen R, Dwyer JT, Goldin BR.: Diet and urinary excretion of lignans in female subjects. *Medical Biology* 59:259 1981.
44. Adlercreutz H, Fotsis T, et al.: Determination of urinary lignans and phytoestrogen metabolites, potential antiestrogens and anticarcinogens in urine of women on various habitual diets. *J Steroid Biochem* 25:791-77, 1986.
45. Adlercreutz H, Hockerstedt K, Hamalainen E, et al.: Lignan and phytoestrogen excretion in Finnish premenopausal omnivorous and vegetarian women and in women with breast cancer. *Scan J Clin Lab Invest* 48, Suppl 190:13-2-Bid 23, 1988.
46. Adlercreutz H, Hockerstedt K, Bannwart C et al.: Association between dietary and fiber, urinary excretion of lignans and isoflavanoic phytoestrogens and plasma non-protein bound sex hormones in relation to breast cancer. *Prog and Cancer Res Therapy* 35:409, 1988.
47. Setchell KDR, Lawson AM, Mitchell FL, Adlercreutz H et al.: Lignans in man and animal species. *Nature* 287:740, 1980.
48. Axelson M, Sjoval J, Gustafson BE, Setchell KDR.: Origins of lignans in mammals and identification of a precursor from plants. *Nature* 298:659, 1982.
49. Drune HM, Patterson DSP, Roberts BA, Subu N.:The chance discovery of oestrogenic activity in laboratory rat soy cake *Food Cosmet Toxicol* 13:491-2, 1975.
50. Setchell KDR, Adlercreutz H.:Mammalian lignands and phyto-estrogens:recent studies on their formation, metabolism and biological role in health and disease. In Rowland IR ed. "Role of the Gut Flora in Toxicity and Cancer" New York:Academic Press, pp315-345, 1988.
51. Barnes S, Grubbs C, Setchell KDR, Carlson J.:Soybeans inhibit mammary tumors in models of breast cancer. In Pariza, ed "Mutagens and Carcinogens in the Diet" New York; Wiley-Liss pp239-53, 1990.
52. Lee HP, Gourley L, Duffy SW et al.:Dietary effects on breast-cancer risk in Singapore. *Lancet* 337:1197,1991.
53. Goldin BR, Adlercreutz H, Gorbach SL, et al.: Estrogen excretion patterns and plasma levels in vegetarian and omnivorous women. *N Engl J Med* 307:1542-1547, 1982.
54. Goldin BR, Adlercreutz H, Gorbach SL, et al.: The relationship between estrogen levels and diets of Caucasian American and Oriental immigrant women. *Am J Clin Nutr* 44:945-953, 1986.
55. Woods MN, Goldin BRA, Gorbach SL, Zumoff B.: The effect of diet estrogens, vitamin D and bone density (abstract) *FED Proc* 43:822, 1984.
56. Gorbach SL, Schaefer EJ, Woods MN, Longcope C, Dwyer JT, Goldin BR, Morrill-LaBrode A, Dallal G.: Plasma lipoproteins cholesterol and endogenous sex hormone in healthy young women. *Metabolism* 38:1077,1989.
57. Longcope C, Gorbach SL, Goldin BR, et al.: The effect of a low-fat diet on estrogen metabolism. *J Clin Endocrinol Metab* 34:113-122, 1974.
58. Woods MN, Gorbach SL, Longcope C. Goldin BR, Dwyer JT, LaBrode-Morrill A.: Low-fat high-fiber diet and serum estrone sulfate in premenopausal women. *Am J Clin Nutr* 49:1170-1183, 1989.
59. Goldin BR, Woods MN, Spiegelman D, Longcope C, Morrill-LaBrode A, Dwyer J, Gualtieri L, Hertzmark E, Gorbach SL.: Dietary fat and fiber influence serum estrogen concentrations in premenopausal women under controlled dietary conditions. (Submitted for publication).
60. Ruder HJ, Loreaux DL, Lipsett MB.: Estrone sulfate production rate and metabolism in man. *J Clin Invest* 51:1020-1033, 1972.



61. Longcope C.: The metabolism of estrone sulfate in normal males. *J Clin Endocrinol Metab.* 34:113-122, 1972.
62. Longcope C, Williams KIH.: The metabolism of estrogens in normal women after pulse injections of 3H-estradiol and 3H-estrone. *J Clin Endocrinol Metab* 38:602-607, 1974.
63. Rose DP, Goldman M, Connolly JM, Strong LE.: High-fiber diet reduces serum estrogen concentrations in premenopausal women. *Am J Clin Nutr* 54:520-525, 1991.
64. Kellogg Foundation Grant
65. Massachusetts Department of Public Health Grant with matching funds from National Cancer Institute.
66. Senie RT.: A study of disease free survival in breast cancer: Contribution of vaginal smear cytology, epidemiology and pathologic factors. Doctoral Dissertation, Yale University, 1984.
67. Senie RT, Lobenthal SW, Rosen PP.: The association of vaginal smear cytology with menstrual status in breast cancer. *Breast Cancer Research and Treatment* 5:301-310, 1985.
68. Senie RT, Rosen PP, Rhodes P, Lesser ML.: Obesity at time of diagnosis influences the survival of women with breast carcinoma. *Annals of Internal Medicine* 116:26-32, 1985.
69. Senie RT, Rosen PP, Rhodes P, Lesser ML.: Menstrual cycle phase at time of tumor excision influences survival of women with breast carcinoma. *Annals of Internal Medicine* 115:337-342, 1991.
70. Borgen PI, Senie RT, Rosen PP, Kinne DW.: Breast cancer survival among males and females matched for age and stage of disease at diagnosis (Submitted for consideration of publication).
71. Senie RT, Borgen PI, Simkovich A, Kinne DW.: Generational shifting in mean age at diagnosis of Breast Cancer (Submitted for publication).
72. Neugarten BL, Kraines RJ.: Menopausal symptoms in women at various ages. *J Psychom Res* 27:266-73, 1965.
73. Swartzmann LC, Edelberg R, Kenmann E.: Impact of stress on objectively recorded hot flushes and on flush bias report. *J Health Psychol* 95(5): 529-45, 1990.
74. Silbur J, Holm K, Dan A.: The relationship of energy expenditure to physical and psychologic symptoms in women at midlife. *Nursing Outlook* 40(6):269-76, 1992.
75. Cook DJ, Greene JG.: Types of life events in relation to symptoms climacterium. *J Psychosom Res* 25:5-11, 1981.
76. Prentice, R, Thompson D, Clifford, et al.: Dietary fat reduction and plasma estradiol concentration among healthy post menopausal women. *JNCI* 82:129-134, 1990.
77. Jones B, Kenward MG.: Design and Analysis of Cross-Over Trials. Chapman and Hall, New York 1989.
78. Donner A.: Approaches to sample size estimation in the design of clinical trials - a review. *Statistics in Medicine.* Volume 3: 199-214, 1984.
79. Cohen J.: Statistical power analysis for the behavioral sciences. Second edition Lawrence Erlbaum Associates. Hillsdale, New Jersey, 1988.
80. Kronenberg F. Hot flashes: Epidemiology and Physiology. *Ann of New York Acad Science* 592:52-84, 1990.
81. Kronenberg, F.: Menopausal hot flashes: thermoregulatory, cardiovascular, and circulating catecholamine and L H changes. *Maturitas* 6:31-43, 1984.
82. St. Jeor S, Guthories HA, Jones MB.: Variability in nutrient intake in a 28 day period. *JADA* 83:155, 1983.
83. Jackson B, Dujoune Ca, Decorsey S et al.: Methods to assess relative reliability of diet records: Minimum records for monitoring lipid and caloric intake, *JADA* 1986 86:1531-5.
84. Willet WC, Sampson L, Stampfer MJ.: Reproducibility and validity of a semiquantitative food frequency questionnaire. *Am J Epidem.* 122:51-65, 1985.
85. Beaton GH, Milner J, McGuire V, Feather TE.: Source of variance in 24 hr dietary recall data-implications for nutrition study design. *Am J Clin Nutr* 37: 37:986-999, 1983.
86. Willett WC, Sampson L, Browne ML, Stampfer MJ, Rosner B, Hennekens CH, Speizer FE: The use of self-administered questionnaire to assess diet four years in the past. *Am J Epid*, 127:188-199, 1988.
87. Abraham GE, Hopper P, Tulchinsky D, Swerdloff RS, Odell WD.: Simultaneous measurement of plasma progesterone, 17-hydroxyprogesterone and estradiol-17 $\beta$  by radioimmunoassay. *Anal Lett* 4:325-333, 1971.
88. Longcope C, Franz C, Morreal C, Baker R, Johnston CC Jr.: Steroid and gonadotrophin levels in women during the peri-menopausal years. *Maturitas* 8:189-196, 1986.
89. Hammond GL, Nisker JA, Jones LA, Siiteri PK.: Estimation of the percent free steroid in undiluted serum by centrifugal ultrafiltration dialysis. *J Biol Chem* 255:5023-5026, 1980.
90. MacMahon W, Stallings J, Sgoutas D.: A simple ultrafiltration method for determining unbound estradiol in serum. *Clin Biochem* 16:240-243, 1983.
91. Longcope C, Hui SL, Johnston CC Jr.: Free estradiol, free testosterone and six hormone-binding globulin in perimenopausal women. *J Clin Endocrinol Metab* 64(3) 513-518, 1987.
92. Mickelson KF, Petra PH.: A filter assay for the sex steroid binding protein. *FEBS Lett* 44:31-33, 1974.
93. Fotsis T.: The multicomponent analysis of estrogens in urine by ion exchange chromatography and GC-MS-I. Quantifications of estrogens after initial hydrolysis of conjugates. *J Steroid Biochemistry* 28:203-213, 1987.
94. Eldridge AC, Determination of isoflavones in soybean flours, protein concentrates and isolates. *J Agric Food Chem*, 20:353, 1982.

## **9. APPENDIX**

- A. Menopausal Questionnaire**
- B. Medical History Form**
- C. Study Log (of menopausal symptoms)**
- D. Seven Day Daily Symptoms Diary**
- E. Food Record Booklet**
- F. Manual Of Operations (MOOP)**
- G. Consent Form - Tufts**
- H. Consent Form - Sloan Kettering**
- I. Recruitment Material - Tufts**
- J. Recruitment Material - Sloan Kettering**
- K. Protein Technology, International (PTI) Supplement Bar  
Nutrient Content**

**A. MENOPAUSAL QUESTIONNAIRE**

**MEDICAL HISTORY QUESTIONNAIRE**  
**Menopausal Symptoms Study (MSS)**

Please answer all questions by filling in the blanks or writing in the information requested. If you need extra room use the back of the form for additional remarks. All information is strictly confidential and will be used only for medical statistical purposes

	___ Boston ___ New York City
1. Today's Date:    ___ / ___ / ___ M M    D D    Y Y	
2. Hospital ID:    _____	Study ID _____
3. Name	_____
4. Address	_____ _____
5. Zip Code:	_____
6. Telephone (Day) (____) _____	
7. Telephone (Eve) (____) _____	
8. Birthdate:    ___ / ___ / ___ M M    D D    Y Y	
9. Age	_____
10. Height	_____ (feet, inches)
11. Weight	_____ (lbs)
12. Marital Status	S   M   W   D
13. Country of Birth	___ United States    ___ South American    ___ Caribbean ___ Other, Name: _____
14. Race	___ Caucasian    ___ African-American    ___ Hispanic ___ Asian    ___ Other
15. Education	Grades Completed (1-12) _____ College (years) _____ Post-college (years) _____
16. In Case of emergency call:	_____ Phone _____

## Pregnancy History

17. Have you ever been pregnant? ☐ No ☐ Yes  
If Yes: a. How many times have you been pregnant?   
b. What was your age when you were first pregnant?   
c. What was your age when your first child was born?   
d. How many pregnancies were not completed?   
Number of miscarriages   
Number of abortions   
e. What was your age at your last pregnancy?
18. Did you breast feed any of your children? ☐ No ☐ Yes  
If yes:  
a. Number of children breastfed   
b. Total number of months of breast feeding

## Menstrual History

19. At what age did your menstrual periods begin?
20. Have you ever had irregular menstrual cycles? ☐ No ☐ Yes  
If yes:  
a. How often did you have irregular menstrual cycles?  
☐ rarely  
☐ consistently or often  
☐ just before menopause  
☐ Other:
- Explain:
21. Have you ever had heavy menstrual flow or severe pain with menstruation? ☐ No ☐ Yes
22. Have you ever had a positive PAP smear? ☐ No ☐ Yes  
If yes:  
a. How many times?   
b. Was this within the last five years ☐ No ☐ Yes
23. How frequent were your menstrual periods?  days  
(Length in days from start of one cycles to start of next cycle)

## Premenopausal History Hormone Use

24. Did you ever use birth control pills?: ☐ No ☐ Yes

If yes: a. How old were you ?

b. How many months did you use them for?  months

Exact dates used if known:  to   
MM/YY MM/YY

c. What type of birth control pills did you use?

Please check

☐ Estrogen only

☐ Estrogen and progesterone

☐ Progesterone only

☐ Not sure

☐ Other:

25. Have you used any other hormone medications prior to menopause such as other pills, patches, creams or suppositories?

Please check.

☐ Androgens

☐ Hormone Patch

☐ Hormone cream

☐ Hormone suppositories

☐ Not sure

☐ Other:

26. Did you ever use any fertility medications? ☐ No ☐ Yes

If yes: Which one did you use? Please check.

☐ DES

☐ Not sure

☐ Other:

## Menopausal History

27. Have you had a period during the last year? ☐ No ☐ Yes ☐ Uncertain

28. When was your your last menstrual period?  /    
MM YY

29. What was your age when you entered menopause?

30. Was your menopause?

☐ Natural

☐ Surgical/hysterectomy (Go to 30a)

☐ Other

a. If surgical, did it include removal of ovaries?

☐ No ☐ Yes

If Yes:

☐ one ovary

☐ both ovaries

☐ don't know

### History of Menopausal Hormone Use

31. Are you currently taking hormones? \_\_\_\_\_ No \_\_\_\_\_ Yes

If yes: Which one? Please Check.

\_\_\_\_\_ Estrogen and progesterone

\_\_\_\_\_ Estrogen only

\_\_\_\_\_ Progesterone only

\_\_\_\_\_ Not sure

\_\_\_\_\_ Other: \_\_\_\_\_

32. Have you taken hormones in the past during menopause? \_\_\_\_\_ No \_\_\_\_\_ Yes

If yes: Which one(s)? Please Check.

\_\_\_\_\_ Estrogen and progesterone

\_\_\_\_\_ Estrogen only

\_\_\_\_\_ Progesterone only

\_\_\_\_\_ Not sure

\_\_\_\_\_ Other: \_\_\_\_\_

b. For how long did you take the hormones? \_\_\_\_\_ months

\_\_\_\_\_ years

c. When did you stop taking the hormones? \_\_\_\_\_ months ago

\_\_\_\_\_ years ago

Dates taken if known: \_\_\_\_\_ to \_\_\_\_\_

### History of Breast Problems

33. Have you ever had a mammogram? \_\_\_\_\_ No \_\_\_\_\_ Yes

If yes: When was the last one? \_\_\_\_\_

34. Have you ever had breast cancer? \_\_\_\_\_ No \_\_\_\_\_ Yes

If yes: What was the date of the diagnosis? \_\_\_\_\_

35. Do you have a history of breast disease? \_\_\_\_\_ No \_\_\_\_\_ Yes

If Yes: What type? Please check.

\_\_\_\_\_ fibrocystic disease

\_\_\_\_\_ breast cysts

\_\_\_\_\_ lobular carcinoma in situ (LCIS)

\_\_\_\_\_ atypical proliferative/ breast disease

\_\_\_\_\_ Other: \_\_\_\_\_

36. Have you ever had a breast aspiration, breast biopsy or breast surgery?

\_\_\_\_ No \_\_\_\_ Yes

If Yes: a. How many breast aspirations and/or biopsies have you had? \_\_\_\_\_

b. For each biopsy (bx) or aspiration (asp), please give the year, the breast affected (l = left, r = right), the type of treatment, the findings of the treatment, and the place performed.

Year	Breast	bx or asp	Findings (normal, abnormal, etc)	Place Performed
19 ____	__l__ r	__bx__asp		
19 ____	__l__ r	__bx__asp		
19 ____	__l__ r	__bx__asp		

### Personal Medical History

37.

DO YOU HAVE A HISTORY OF:	NO	YES	IF YES, PLEASE EXPLAIN
High blood pressure			
Heart Disease			
Diabetes Mellitus			
Pancreatic Disease			
Liver Disease			
Bleeding Disorder			
Hyperlipidemia (high fats in blood)			
Kidney disease			
Small Bowel Disease			
Atrophic Gastritis			
Cancer			Type:
Prior radiation to the chest or breast			
Thyroid Disease			
Urinary tract infection			Number of times in last 5 years _____
Other			Explain:



38. What was the date of your last physical exam? \_\_\_\_\_

a. Who is your primary care physician?  
(please give address and phone if known) \_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

39. Please list all operations and surgeries you have had?

Type of operation:	Date of operation:

40. Please list all medications you are currently taken, indicate the condition being treated and the date you started taking the medication,

Medication	Condition being treated	Date Medication Started

41. Please list all allergies (i.e. medications, foods, other)

42. Has your weight changed more than 10 lbs in the last two years? \_\_\_\_\_ No    \_\_\_\_\_ Yes  
If Yes, explain:

## Family History of Cancer

43. To the best of your knowledge, have any of your blood relatives (living or dead) ever had cancer? \_\_\_\_\_ No \_\_\_\_\_ Yes

If yes, please fill in the table below using the key at the bottom of the page:

**Note:** Please list separately each cancer for each relative. If breast cancer, please indicate if both breasts were affected. (Please see the example given in the shaded area)

Relative	Type of Cancer	Age at Diagnosis	Were both breasts affected?
6	Breast Cancer	45	No

- |                          |                           |                            |
|--------------------------|---------------------------|----------------------------|
| 1 = mother               | 8 = maternal first cousin | 15 = paternal grandfather  |
| 2 = sister               | 9 = other (maternal)      | 16 = paternal aunt         |
| 3 = daughter             | 10 = other (maternal)     | 17 = paternal uncle        |
| 4 = maternal grandmother | 11 = father               | 18 = paternal first cousin |
| 5 = maternal grandfather | 12 = brother              | 19 = other (paternal)      |
| 6 = maternal aunt        | 13 = son                  | 20 = other (paternal)      |
| 7 = maternal uncle       | 14 = paternal grandmother |                            |

(Maternal = Mother's side of family    Paternal = Father's side of family)

## Smoking and Alcohol History

44. Are you currently a smoker? No \_\_\_\_\_ Yes \_\_\_\_\_

If Yes:

How many cigarettes do you smoke each day? \_\_\_\_\_

45. Have you smoked a total of 100 cigarettes in your lifetime? No \_\_\_\_\_ Yes \_\_\_\_\_

If Yes:

a. How old were you when you began to smoke cigarettes? \_\_\_\_\_ years

b. How old were you when you last smoked cigarettes? \_\_\_\_\_ years

c. How many cigarettes did you usually smoke each day? \_\_\_\_\_

46. Have you ever lived in the same house with a smoker? No \_\_\_\_\_ Yes \_\_\_\_\_

If yes:

For how many years did you live with a smoker? \_\_\_\_\_

47. Do you drink one or more alcoholic beverages per week? No \_\_\_\_\_ Yes \_\_\_\_\_

If yes:

a. How many alcoholic drinks do you have per week? \_\_\_\_\_

b. When you choose an alcoholic beverage what do you usually choose?

(Check all that apply)

\_\_\_\_ Beer

\_\_\_\_ Wine

\_\_\_\_ Spritzer

\_\_\_\_ Hard liquor (scotch, bourbon, whiskey, gin, etc.)

## Exercise History

48. During the past year what was your average time per week in minutes spent at each of the following activities?

Activities	Minutes per week
Walking or hiking outdoors (include walking to work)	
Jogging (slower than 10 minutes/mile)	
Running (10 minutes/mile or faster)	
Bicycling or stationary bicycle	
Cross country ski machine	
Swimming	
Tennis/Squash or Racquetball	
Aerobics/Dance Class	
Calisthenics	
Weight Lifting	
Other exercise (please specify):	

**B. MEDICAL HISTORY FORM**

# Menopausal Symptoms Questionnaire

I.D. \_\_\_\_\_

Clinic: \_\_\_\_\_ Boston  
 \_\_\_\_\_ New York

Date: \_\_\_\_\_

Please indicate whether you have experienced any of the following symptoms in the **past month**. If yes, check the Frequency, circle the Usual Intensity and then if the Usual Intensity varies check the Intensity Varies Column. For example, if during the last month you had joint pain once or twice a week you would check the Weekly column and leave the Daily and Monthly columns blank. Then you would circle the Usual Intensity Mild (1), Moderate (3) or Severe (5) and if the usual intensity varies check the Intensity Varies column.

EXAMPLE:

		Frequency (Check One)			Usual Intensity (Circle one)			Intensity Varies
		Daily	Weekly	Monthly	Mild	Moderate	Severe	
1. Joint pain	<input type="checkbox"/> No <input checked="" type="checkbox"/> Yes	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	1	③	5	<input checked="" type="checkbox"/>

		Frequency (Check One)			Usual Intensity (Circle one)			Intensity Varies
		Daily	Weekly	Monthly	Mild	Moderate	Severe	
1. Hot flashes/flushes	<input type="checkbox"/> No <input type="checkbox"/> Yes	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	1	3	5	<input type="checkbox"/>
2. Increased heart rate (palpitations) when you <u>are having hot flashes</u>	<input type="checkbox"/> No <input type="checkbox"/> Yes	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	1	3	5	<input type="checkbox"/>
3. Increased heart rate (palpitations) when <u>not having hot flashes</u>	<input type="checkbox"/> No <input type="checkbox"/> Yes	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	1	3	5	<input type="checkbox"/>
4. Trouble sleeping for reasons <u>other than</u> hot flashes	<input type="checkbox"/> No <input type="checkbox"/> Yes	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	1	3	5	<input type="checkbox"/>
5. Headaches or migraines that disrupt your normal activity	<input type="checkbox"/> No <input type="checkbox"/> Yes	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	1	3	5	<input type="checkbox"/>
6. Muscle aches, pains or stiffness preventing mobility	<input type="checkbox"/> No <input type="checkbox"/> Yes	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	1	3	5	<input type="checkbox"/>
7. Joint pain	<input type="checkbox"/> No <input type="checkbox"/> Yes	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	1	3	5	<input type="checkbox"/>
8. Vaginal dryness	<input type="checkbox"/> No <input type="checkbox"/> Yes	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	1	3	5	<input type="checkbox"/>
9. Increased frequency of urination	<input type="checkbox"/> No <input type="checkbox"/> Yes	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	1	3	5	<input type="checkbox"/>
10. Urinary leakage when coughing, sneezing or during orgasm	<input type="checkbox"/> No <input type="checkbox"/> Yes	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	1	3	5	<input type="checkbox"/>
11. Sudden/unexplained mood swings	<input type="checkbox"/> No <input type="checkbox"/> Yes	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	1	3	5	<input type="checkbox"/>
12. Periods of unexplained anxiety	<input type="checkbox"/> No <input type="checkbox"/> Yes	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	1	3	5	<input type="checkbox"/>
13. Periods of unexplained fatigue	<input type="checkbox"/> No <input type="checkbox"/> Yes	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	1	3	5	<input type="checkbox"/>
14. Difficulty remembering things	<input type="checkbox"/> No <input type="checkbox"/> Yes	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	1	3	5	<input type="checkbox"/>
15. Fluid retention: Bloating	<input type="checkbox"/> No <input type="checkbox"/> Yes	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	1	3	5	<input type="checkbox"/>
16. Indigestion	<input type="checkbox"/> No <input type="checkbox"/> Yes	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	1	3	5	<input type="checkbox"/>

17. Other \_\_\_\_\_      \_\_\_No \_\_\_Yes      \_\_\_\_\_ 1      3      5      \_\_\_\_\_

**Please answer the following questions based on what you have experienced during the last month.**

18. Do you usually sweat during a hot flash?      \_\_\_\_\_ No      \_\_\_\_\_ Yes

19. Is there anything that has made your hot flashes more likely to occur?      \_\_\_\_\_ No      \_\_\_\_\_ Yes  
If yes, explain:

20. Is there anything that has made your hot flashes less likely to occur?      \_\_\_\_\_ No      \_\_\_\_\_ Yes  
If yes, explain:

21. Have you experienced any bleeding or spotting?      \_\_\_\_\_ No      \_\_\_\_\_ Yes  
If yes, explain

22. Has your pattern of hot flashes changed?      \_\_\_\_\_ No      \_\_\_\_\_ Yes  
If yes, explain

23. Have you had any changes in medical conditions ?      \_\_\_\_\_ No      \_\_\_\_\_ Yes  
If yes, explain

24. Have you had any changes in medications that you are taking ?      \_\_\_\_\_ No      \_\_\_\_\_ Yes  
If yes, explain

25. Have you taken any antibiotics?      \_\_\_\_\_ No      \_\_\_\_\_ Yes  
If yes, explain

26. Have you experienced any of the following during the past month? If yes please indicate when.

	No	Yes	When
A. Illness of Relative	_____	_____	_____
B. Death of Family Member	_____	_____	_____
C. Death of Close Friend	_____	_____	_____
D. Divorce	_____	_____	_____
E. Major Vacation	_____	_____	_____
F. Personal Illness	_____	_____	_____
G. Loss of Job	_____	_____	_____
H. Moving	_____	_____	_____

27. Have you experienced any other significant life events recently?

No\_\_\_ Yes\_\_\_

If yes, explain:

28. In the last month have you tried any alternative therapies (in addition to regular medical care or the study requirements) to help you with your menopausal symptoms or other medical problems?

Therapies	No	Yes	Type/Kind	For which symptom or problem did you try the therapy?
A. Herbal teas	_____	_____	_____	_____
B. Relaxation	_____	_____	_____	_____
C. Meditation	_____	_____	_____	_____
D. Chiropractic	_____	_____	_____	_____
E. Acupuncture	_____	_____	_____	_____
F. Change in Diet	_____	_____	_____	_____
G. Vitamins/ Supplements	_____	_____	_____	_____
H. Other	_____	_____	_____	_____
			_____	_____
			_____	_____
			_____	_____



**C. STUDY LOG (of menopausal symptoms)**



## Study Log

Study I.D.#: \_ \_ \_

Dates: \_ \_ - \_ \_ - \_ \_ to \_ \_ - \_ \_ - \_ \_  
MM DD YY MM DD YY

Clinic:(Circle) Boston New York City

## **INSTRUCTIONS FOR COMPLETION OF YOUR STUDY LOG**

**This diary will collect daily information on:**

- 1. Day of week and date**
- 2. Number of hot flashes experienced during daytime (waking hours) and nighttime (sleeping hours)**
- 3. The number of dietary supplement bars consumed each day.**
- 4. Notes on medications, illness, travel etc.**

**Definition of hot flash:** We are considering the terms hot flash, hot flush, and night sweats to be the same. These are typically sudden episodes of feeling warm, flushing, and/or sweating. These events can take place during the day or night and we are tracking the daytime hot flashes separately from the nighttime hot flashes.

## **NUMBER OF HOT FLASHES**

Record the total number of hot flashes you have each day.

Before you go to sleep, write the number of hot flashes you had during the day in the daytime column. Write Q if you did not have any hot flashes that day.

When you get up in the morning, record the number of hot flashes you had between the time you went to sleep and the time you woke up in the morning. Write Q if you did not have any hot flashes during the night.

### **EXAMPLE**

On Sunday January 1, 1995 Jane Smith had three hot flashes during the day before she went to bed and no hot flashes between the time she went to sleep Monday night and woke up Tuesday morning. Also on Monday Jane ate only 1 of the dietary supplement bars.

On Monday January 2, 1995 Jane did not have any hot flashes during the day, but after she went to sleep she had four hot flashes during the night. On Monday Jane ate both of the dietary supplement bars.

Please refer to the sample on the next page to see how this information would be recorded.

# **SAMPLE**

WEEK OF 1/1/95 TO 1/7/95				
		Number of Hot Flashes		Dietary Bars Taken (Circle)
DAY	DATE	Waking Hours	Sleeping Hours	
Sunday	1/1	3	0	0 ① 2
Monday	1/2	0	4	0 1 ②
Tuesday	1/3			0 1 2
Wed	1/4			0 1 2
Thursday	1/5			0 1 2
Friday	1/6			0 1 2
Saturday	1/7			0 1 2

**NOTES:**  
*On New Years Day I was out all day and forget to eat my second soy bar.*

WEEK OF		TO		
		Number of Hot Flashes		Dietary Bars Taken (Circle)
DAY	DATE	Waking Hours	Sleeping Hours	
Sunday				0 1 2
Monday				0 1 2
Tuesday				0 1 2
Wed				0 1 2
Thursday				0 1 2
Friday				0 1 2
Saturday				0 1 2
NOTES:				

WEEK OF		TO		
		Number of Hot Flashes		Dietary Bars Taken (Circle)
DAY	DATE	Waking Hours	Sleeping Hours	
Sunday				0 1 2
Monday				0 1 2
Tuesday				0 1 2
Wed				0 1 2
Thursday				0 1 2
Friday				0 1 2
Saturday				0 1 2
NOTES:				

WEEK OF		TO		
		Number of Hot Flashes		Dietary Bars Taken (Circle)
DAY	DATE	Waking Hours	Sleeping Hours	
Sunday				0 1 2
Monday				0 1 2
Tuesday				0 1 2
Wed				0 1 2
Thursday				0 1 2
Friday				0 1 2
Saturday				0 1 2
NOTES:				



WEEK OF		TO		
		Number of Hot Flashes		Dietary Bars Taken (Circle)
DAY	DATE	Waking Hours	Sleeping Hours	
Sunday				0 1 2
Monday				0 1 2
Tuesday				0 1 2
Wed				0 1 2
Thursday				0 1 2
Friday				0 1 2
Saturday				0 1 2
NOTES:				

WEEK OF		TO		
		Number of Hot Flashes		Dietary Bars Taken (Circle)
DAY	DATE	Waking Hours	Sleeping Hours	
Sunday				0 1 2
Monday				0 1 2
Tuesday				0 1 2
Thursday				0 1 2
Wed				0 1 2
Friday				0 1 2
Saturday				0 1 2
NOTES:				

**D. SEVEN DAY DAILY SYMPTOMS DIARY**



## Seven Day Daily Symptoms Diary

Study I.D.#: \_ \_ \_

Dates: \_ \_ - \_ - \_ to \_ \_ - \_ - \_  
MM DD YY MM DD YY

Clinic: (Circle) Boston New York City

Phase: (Circle) S B I II III

## **Instructions for Completion of Your Seven Day Daily Symptoms Diary**

**This diary will collect daily information on the:**

- **Number of dietary supplement bars consumed each day**
- **Date and time of all hot flashes that occur during a specified seven day period.**
- **Intensity of each hot flash**
- **Notes on medications, illness, travel, etc.**

**This booklet contains 1 double sided page for each day. Please start a new page for each day and record the date at the top of the page.**

### **Number of dietary supplement bars eaten:**

**Each day circle the number of dietary supplement bars eaten (0 1 2).**

**Definition of hot flashes: We are considering the terms hot flash, hot flush, and night sweats to be the same. These are typically sudden episodes of feeling warm, flushing, and/or sweating. These events can take place during the day or night.**

Number of Hot Flashes: Record the time of each individual hot flash when it occurs or as soon as possible afterwards.

Hot Flash Intensity: We would also like you to pay attention to the severity or intensity of your hot flashes and to rate them on a scale of 1 to 5:

- |            |   |
|------------|---|
| 1=Mild     | a slight feeling of warmth with little or no perspiration   |
| 3=Moderate | warmer than a mild hot flash, definitely noticeable and producing obvious sensible perspiration                                 |
| 5=Severe   | feeling intensely hot, with profuse perspiration, perhaps an unsettling feeling or feeling momentarily disrupted or debilitated |

Notes: Use the Notes section daily to record circumstances that may effect the number or severity of your hot flashes. For example, if you feel ill or stressed, take medications, experience conditions that are unusually hot or cold, etc.

**Day 1****Date:****Dietary Supplements taken: 0 1 2 (Circle one)**

<b>Hot Flash</b>	<b>TIME Indicate AM/PM</b>	<b>Intensity (Circle one)</b>		
		<u>Mild</u>	<u>Moderate</u>	<u>Severe</u>
1		1	3	5
2		1	3	5
3		1	3	5
4		1	3	5
5		1	3	5
6		1	3	5
7		1	3	5
8		1	3	5
9		1	3	5
10		1	3	5
11		1	3	5
12		1	3	5
13		1	3	5
14		1	3	5

**Day 1 (continued)**

<b>Hot Flash</b>	<b>TIME</b> Indicate AM/PM	<b>Intensity (Circle one)</b>		
		<b>Mild</b>	<b>Moderate</b>	<b>Severe</b>
15		1	3	5
16		1	3	5
17		1	3	5
18		1	3	5
19		1	3	5
20		1	3	5
21		1	3	5
22		1	3	5
23		1	3	5
24		1	3	5

**Notes:**



**Day 2****Date:****Dietary Supplements taken: 0 1 2 (Circle one)**

<b>Hot Flash</b>	<b>TIME Indicate AM/PM</b>	<b>Intensity (Circle one)</b>		
		<u>Mild</u>	<u>Moderate</u>	<u>Severe</u>
1		1	3	5
2		1	3	5
3		1	3	5
4		1	3	5
5		1	3	5
6		1	3	5
7		1	3	5
8		1	3	5
9		1	3	5
10		1	3	5
11		1	3	5
12		1	3	5
13		1	3	5
14		1	3	5

**Day 2 (continued)**

<b>Hot Flash</b>	<b>TIME Indicate AM/PM</b>	<b>Intensity (Circle one)</b>		
		<u>Mild</u>	<u>Moderate</u>	<u>Severe</u>
15		1	3	5
16		1	3	5
17		1	3	5
18		1	3	5
19		1	3	5
20		1	3	5
21		1	3	5
22		1	3	5
23		1	3	5
24		1	3	5

**Notes:**

**Day 3****Date:****Dietary Supplements taken: 0 1 2 (Circle one)**

Hot Flash	TIME Indicate AM/PM	Intensity (Circle one)		
		<u>Mild</u>	<u>Moderate</u>	<u>Severe</u>
1		1	3	5
2		1	3	5
3		1	3	5
4		1	3	5
5		1	3	5
6		1	3	5
7		1	3	5
8		1	3	5
9		1	3	5
10		1	3	5
11		1	3	5
12		1	3	5
13		1	3	5
14		1	3	5

**Day 3 (continued)**

<b>Hot Flash</b>	<b>TIME Indicate AM/PM</b>	<b>Intensity (Circle one)</b>		
		<u>Mild</u>	<u>Moderate</u>	<u>Severe</u>
15		1	3	5
16		1	3	5
17		1	3	5
18		1	3	5
19		1	3	5
20		1	3	5
21		1	3	5
22		1	3	5
23		1	3	5
24		1	3	5

**Notes:**

**Day 4****Date:****Dietary Supplements taken: 0 1 2 (Circle one)**

Hot Flash	TIME Indicate AM/PM	Intensity (Circle one)		
		<u>Mild</u>	<u>Moderate</u>	<u>Severe</u>
1		1	3	5
2		1	3	5
3		1	3	5
4		1	3	5
5		1	3	5
6		1	3	5
7		1	3	5
8		1	3	5
9		1	3	5
10		1	3	5
11		1	3	5
12		1	3	5
13		1	3	5
14		1	3	5

**Day 4 (continued)**

<b>Hot Flash</b>	<b>TIME</b> Indicate AM/PM	<b>Intensity (Circle one)</b>		
		<u>Mild</u>	<u>Moderate</u>	<u>Severe</u>
15		1	3	5
16		1	3	5
17		1	3	5
18		1	3	5
19		1	3	5
20		1	3	5
21		1	3	5
22		1	3	5
23		1	3	5
24		1	3	5

**Notes:**

**Day 5****Date:****Dietary Supplements taken: 0 1 2 (Circle one)**

<b>Hot Flash</b>	<b>TIME Indicate AM/PM</b>	<b>Intensity (Circle one)</b>		
		<u>Mild</u>	<u>Moderate</u>	<u>Severe</u>
1		1	3	5
2		1	3	5
3		1	3	5
4		1	3	5
5		1	3	5
6		1	3	5
7		1	3	5
8		1	3	5
9		1	3	5
10		1	3	5
11		1	3	5
12		1	3	5
13		1	3	5
14		1	3	5

**Day 5 (continued)**

<b>Hot Flash</b>	<b>TIME</b> Indicate AM/PM	<b>Intensity (Circle one)</b>		
		<u>Mild</u>	<u>Moderate</u>	<u>Severe</u>
15		1	3	5
16		1	3	5
17		1	3	5
18		1	3	5
19		1	3	5
20		1	3	5
21		1	3	5
22		1	3	5
23		1	3	5
24		1	3	5

**Notes:**



**Day 6****Date:****Dietary Supplements taken: 0 1 2 (Circle one)**

<b>Hot Flash</b>	<b>TIME Indicate AM/PM</b>	<b>Intensity (Circle one)</b>		
		<u>Mild</u>	<u>Moderate</u>	<u>Severe</u>
1		1	3	5
2		1	3	5
3		1	3	5
4		1	3	5
5		1	3	5
6		1	3	5
7		1	3	5
8		1	3	5
9		1	3	5
10		1	3	5
11		1	3	5
12		1	3	5
13		1	3	5
14		1	3	5

**Day 6 (continued)**

<b>Hot Flash</b>	<b>TIME</b> Indicate AM/PM	<b>Intensity (Circle one)</b>		
		<u>Mild</u>	<u>Moderate</u>	<u>Severe</u>
15		1	3	5
16		1	3	5
17		1	3	5
18		1	3	5
19		1	3	5
20		1	3	5
21		1	3	5
22		1	3	5
23		1	3	5
24		1	3	5

**Notes:**

**Day 7****Date:****Dietary Supplements taken: 0 1 2 (Circle one)**

<b>Hot Flash</b>	<b>TIME Indicate AM/PM</b>	<b>Intensity (Circle one)</b>		
		<u>Mild</u>	<u>Moderate</u>	<u>Severe</u>
1		1	3	5
2		1	3	5
3		1	3	5
4		1	3	5
5		1	3	5
6		1	3	5
7		1	3	5
8		1	3	5
9		1	3	5
10		1	3	5
11		1	3	5
12		1	3	5
13		1	3	5
14		1	3	5

**Day 7 (continued)**

<b>Hot Flash</b>	<b>TIME Indicate AM/PM</b>	<b>Intensity (Circle one)</b>		
		<u>Mild</u>	<u>Moderate</u>	<u>Severe</u>
15		1	3	5
16		1	3	5
17		1	3	5
18		1	3	5
19		1	3	5
20		1	3	5
21		1	3	5
22		1	3	5
23		1	3	5
24		1	3	5

**Notes:**

**E. FOOD RECORD BOOKLET**



## FOOD RECORD

Date of Intake:           -           -            
                  m m           d d           y y

Participant's ID#:               

Participant's Sex: M F (Circle)

Birth Date:           -           -            
                  m m           d d           y y

Interviewer's ID#:               

Clinic: (Circle)	Boston	New York
Phase: (Circle)	0	I II III

7

6

5

4

3

2

1

Circle Day: Su M T W TH Fr Sa Date: \_\_\_\_\_

**SAMPLE DESCRIPTION**

	Time	Place	Meal	FOOD/BEVERAGE DESCRIPTION	Amount	TNDC
1	12 P	3	S	Pear, Fresh, 3" diameter w/peel	1 ea.	
2						
3	3 P	3	S	Coke, regular, no ice	12 oz.	
4				Granola Bar, Nature Valley, Cinnamon	1.5 oz.	
5						
6	6 P	1	D	Lasagna (recipe)	1/8 recipe	
7				ground beef, regular, fat	1 lb.	
8				3" onion	1 ea.	
9				clove, garlic	1 ea.	
10				16 oz. can tomatoes	1 ea.	
11				3 oz. can tomato paste	1 ea.	
12				basil	2 tsp.	
13				salt	1 tsp.	
14				lasagna, noodles, dry	1 lb.	
15				Mazola Corn oil	1 TB	
16				eggs, large	2 ea.	
17				Ricotta skim milk cheese	1 lb.	
18				Parmesan cheese, dry, grated	3/4 cup	
19				Parsley leaves, dried	2 TB	
20				Mozzarella, cheese, part skim	1 lb.	
21				Tca, herbal	1 cup	
22				Graham crackers, plain, Nabisco, 5x2 1/2	2 ea.	

Menopausal Symptom Study

**GUIDELINES FOR KEEPING  
A FOOD RECORD**



## Guidelines For Keeping A Food Record

1. 3 Day Food Record: Start your food record at midnight (12:01 a.m.) on day one and keep it until midnight (12:00 p.m.) on the last day. Include one weekend day.
2. Record foods and beverages immediately after eating or drinking.
  - use pen
  - include vitamin and mineral supplements and over-the-counter medications
  - do not change present eating habits during collection of food record
  - include all meals, snacks and beverages actually consumed anytime of the day or night.
  - if "diet" or other special product, copy nutrition information from label
  - include type and amount of added fat, all seasonings, sauces, and condiments
  - use brand name wherever possible
3. Start a new page for each day. Use as many pages as needed.
4. List only one food per line. Skip a line between each meal.
5. Time: Record the time to the nearest hour and whether meal was consumed in A.M. or P.M.
6. Place: Indicate where food was prepared:
  - Home = 1; Restaurant = 2, to indicate an expensive restaurant, use Ex and for an inexpensive restaurant, use Inex.
  - Other = 3, indicate whether fast food, day care, friend's, delicatessen or cafeteria.
7. Meal: Indicate: Breakfast = B, Lunch = L, Dinner = D, Snack = S.
8. Describing Amounts:
  - Measure all liquids using a clear measuring cup and record in cups. (Example: milk, 2% 3/4 C.)
  - If scales are not available, measure the portion consumed using tablespoons (TB), teaspoons (tsp.), cups (C), inches (in), or list the number of small items (Example: 15 raisins).
  - When using your measuring cup to measure solids, report the amount in cups, not ounces. (Example: 1 cup cereal).

- If describing a portion in inches, use appropriate measurements, such as:
  - spherical food diameter, e.g. orange, 3" d
  - round food: diameter and height, e.g., cookies, 3" d x 1/4" ht.
  - square or rectangular food: length, width and height, e.g. brownie, 2" 1 x 3" w x 1/2" ht.
  - wedge food: arc, height and length, e.g. pie, 3" arc x 1" ht x 4" 1 or diameter of whole and proportion, ( e.g.) 1/8th of 8" pie.
- 9. Describing foods, beverages and supplements:  
Protein Foods:  
Meat, Fish, and Poultry:
  - cooked or raw weights, trimmed, partially trimmed or untrimmed
  - with or without bone/shell
  - method of preparation
  - type, cut or part, grade or % fat
  - light or dark poultry
  - with or without skin
  - oil or water packed fishLegumes, Nuts and Seeds:
  - dry or cooked weightsEggs and Substitutes:
  - size
  - method of preparationSoups:
  - cream, milk (%) or water-based
  - regular or chunky
  - modified or regularFats And Oils:
  - brand
  - form (stick, tub, liquid)
  - type (regular, light, diet, unsalted)Milk Products:
  - type or percent fat
  - dairy or non-dairy
  - liquid or powderGrains And Mixtures:
  - type of grain or flour
  - recipe if homemade or mix
  - thick or thin crust pizzaDesserts:
  - single or double crust pies

- cake or yeast donut
- Vegetables And Mixtures:
- cooked or raw weight
  - method of preparation
  - fresh, frozen or canned
- Fruit And Mixtures:
- fresh, frozen, canned or dried
  - cooked or raw weight
  - sweetened or unsweetened
- Sweets:
- description or recipe
- Beverages:
- 
- Alcohol And Other Beverages:
- proof
  - amount without ice
  - light or regular beer
  - table or dessert wine
  - liquor or liqueur
  - regular or diet
  - with or without caffeine
  - brewed or instant
  - decaffeinated or herbal tea and coffee
- Seasonings:
- 
- Include all -
- herbs and spices
  - condiments and sauces
  - meat tenderizer and MSG
  - salts - regular or modified, plain or seasoned
  - use measuring spoons if possible
  - include all additions in cooking or at the table
- Supplements And Over The Counter Medications:
- brand and complete name
  - number of tablets or size of dosage taken
10. Recipes:
- For each recipe used
- Record no more than one ingredient per line.
  - If the recipe is consumed again, indicate the new serving size in the same measurements as before.
  - No cooking directions are required.
  - Record total yield of recipe and amount eaten in the same measurement, or record proportion of total recipe eaten.
- 11 .After completing your food record, go back to the guidelines and check each item listed to make sure you have followed all the instructions.

## APPOINTMENT INFORMATION:

Begin your Record on \_\_\_\_\_,  
day

\_\_\_\_ - \_\_\_\_ - \_\_\_\_ through \_\_\_\_\_,  
m m d d y y day

\_\_\_\_ - \_\_\_\_ - \_\_\_\_  
m m d d y y

Please contact me if any questions arise at:  
tel. #: \_\_\_\_\_

Your next appointment is \_\_\_\_ - \_\_\_\_ - \_\_\_\_  
m m d d y y

Are the three days recorded in this booklet typical of your  
usual food intake?

Circle:      Yes              No

If no, explain why?

---

---

---

---

## GUIDELINES FOR KEEPING A FOOD RECORD

1. 3 Day Food Record: Start your food record at midnight (12:01 a.m.) on day one and keep it until midnight (12:00 p.m.) on the last day. Include one weekend day.

2. Record foods and beverages immediately after eating or drinking.

- use pen
- include vitamin and mineral supplements and over-the counter medications

do not change present eating habits during collection of food record

- include all meals, snacks and beverages actually consumed anytime of the day or night.
- if "diet" or other special product, copy nutrition information from label
- include type and amount of added fat, all seasonings, sauces, and condiments
- use brand name wherever possible

3. Start a new page for each day. Use as many pages as needed.

4. List only one food per line. Skip a line between each meal.

5. Time: Record the time to the nearest hour and whether meal was consumed in A.M. or P.M.

6. Place: Indicate where food was prepared:

- Home = 1; Restaurant = 2, to indicate an expensive restaurant, use Ex and for an inexpensive restaurant, use Inex.
- Other = 3, indicate whether fast food, day care, friend's, delicatessen or cafeteria.

## GUIDELINES (continued)

7. Meal: Indicate: Breakfast = B, Lunch = L,  
Dinner = D, Snack = S.

### 8. Describing Amounts:

- Measure all liquids using a clear measuring cup and record in cups. (Example: milk, 2%  $3/4$  C.)
- If scales are not available, measure the portion consumed using tablespoons (TB), teaspoons (tsp), cups (C), inches (in), or list the number of small items (Example: 15 raisins).
- When using your measuring cup to measure solids, report the amount in cups, not ounces. (Example: 1 cup cereal).
- If describing a portion in inches, use appropriate measurements, such as:
  - spherical food diameter, e.g. orange, 3" d
  - round food: diameter and height, e.g., cookies, 3" d x  $1/4$ " ht.
  - square or rectangular food: length, width and height, e.g. brownie, 2" l x 3" w x  $1/2$ " ht.
  - wedge food: arc, height and length, e.g. pie, 3" arc x 1" ht x 4" l or diameter of whole and proportion, ( e.g.)  $1/8$ th of 8" pie.

### 9. Describing foods, beverages and supplements:

#### PROTEIN FOODS:

##### Meat, Fish, and Poultry:

- cooked or raw weights, trimmed, partially trimmed or untrimmed
- with or without bone/shell
- method of preparation
- type, cut or part, grade or % fat
- light or dark poultry
- with or without skin
- oil or water packed fish

Protein (continued)

Legumes, Nuts and Seeds:

- dry or cooked weights

Eggs and Substitutes:

- size
- method of preparation

Soups:

- cream, milk (%) or water-based
- regular or chunky
- modified or regular

FATS AND OILS:

- brand
- form (stick, tub, liquid)
- type (regular, light, diet, unsalted)

MILK PRODUCTS:

- type or percent fat
- dairy or non-dairy
- liquid or powder

GRAINS AND MIXTURES:

- type of grain or flour
- recipe if homemade or mix
- thick or thin crust pizza

Desserts:

- single or double crust pies
- cake or yeast donut

VEGETABLES AND MIXTURES:

- cooked or raw weight
- method of preparation
- fresh, frozen or canned

FRUIT AND MIXTURES:

- fresh, frozen, canned or dried
- cooked or raw weight
- sweetened or unsweetened

SWEETS:

- description or recipe

## BEVERAGES:

### Alcohol And Other Beverages:

- proof
- amount without ice
- light or regular beer
- table or dessert wine
- liquor or liqueur
- regular or diet
- with or without caffeine
- brewed or instant
- decaffeinated or herbal tea and coffee

## SEASONINGS:

### Include all -

- herbs and spices
- condiments and sauces
- meat tenderizer and MSG
- salts - regular or modified, plain or seasoned
- use measuring spoons if possible
- include all additions in cooking or at the table

## SUPPLEMENTS AND OVER THE COUNTER MEDICATIONS:

- brand and complete name
- number of tablets or size of dosage taken

### 10. Recipes: For each recipe used

- Record no more than one ingredient per line.
- If the recipe is consumed again, indicate the new serving size in the same measurements as before.
- No cooking directions are required.
- Record total yield of recipe and amount eaten in the same measurement, or record proportion of total recipe eaten.

11. After completing your food record, go back to the guidelines and check each item listed to make sure you have followed all the instructions.

Circle Day: Su M T W TH Fr Sa

	Time	Place	Meal	FOOD/BEVERAGE DESCRIPTION
1				
2				
3				
4				
5				
6				
7				
8				
9				
10				
11				
12				
13				
14				
15				
16				
17				
18				
19				
20				
21				
22				

**Date:** \_\_\_\_ - \_\_\_\_ - \_\_\_\_

[illegible]



Circle Day: Su M T W TH Fr Sa

	Time	Place	Meal	FOOD/BEVERAGE DESCRIPTION
23				
24				
25				
26				
27				
28				
29				
30				
31				
32				
33				
34				
35				
36				
37				
38				
39				
40				
41				
42				
43				
44				

**Date:** \_\_\_\_ - \_\_\_\_ - \_\_\_\_

[illegible]

Circle Day: Su M T W TH Fr Sa

	Time	Place	Meal	FOOD/BEVERAGE DESCRIPTION
45				
46				
47				
48				
49				
50				
51				
52				
53				
54				
55				
56				
57				
58				
59				
60				
61				
62				
63				
64				
65				
66				

**Date:** \_\_\_\_ - \_\_\_\_ - \_\_\_\_

[illegible]

Circle Day: Su M T W TH Fr Sa

	Time	Place	Meal	FOOD/BEVERAGE DESCRIPTION
67				
68				
69				
70				
71				
72				
73				
74				
75				
76				
77				
78				
79				
80				
81				
82				
83				
84				
85				
86				
87				
88				

Date: \_\_\_\_-\_\_\_\_-\_\_\_\_

[illegible]

**Circle Day: Su M T W TH Fr Sa**

	Time	Place	Meal	FOOD/BEVERAGE DESCRIPTION
89				
90				
91				
92				
93				
94				
95				
96				
97				
98				
99				
100				
101				
102				
103				
104				
105				
106				
107				
108				
109				
110				

Date: \_\_\_\_\_

[illegible]



Circle Day: Su M T W TH Fr Sa

	Time	Place	Meal	FOOD/BEVERAGE DESCRIPTION
111				
112				
113				
114				
115				
116				
117				
118				
119				
120				
121				
122				
123				
124				
125				
126				
127				
128				
129				
130				
131				
132				



Circle Day: Su M T W TH Fr Sa

	Time	Place	Meal	FOOD/BEVERAGE DESCRIPTION
133				
134				
135				
136				
137				
138				
139				
140				
141				
142				
143				
144				
145				
146				
147				
148				
149				
150				
151				
152				
153				
154				

**Date:** \_\_\_\_ - \_\_\_\_ - \_\_\_\_

[illegible]

Circle Day: Su M T W TH Fr Sa

	Time	Place	Meal	FOOD/BEVERAGE DESCRIPTION
155				
156				
157				
158				
159				
160				
161				
162				
163				
164				
165				
166				
167				
168				
169				
170				
171				
172				
173				
174				
175				
176				

**Date:** \_\_\_\_ - \_\_\_\_ - \_\_\_\_

[illegible]

Circle Day: Su M T W TH Fr Sa

	Time	Place	Meal	FOOD/BEVERAGE DESCRIPTION
177				
178				
179				
180				
181				
182				
183				
184				
185				
186				
187				
188				
189				
190				
191				
192				
193				
194				
195				
196				
197				
198				

**Date:** \_\_\_\_ - \_\_\_\_ - \_\_\_\_

[illegible]



# NOTES

**TO BE COMPLETED BY INTERVIEWER:**

Interviewer's ID#: \_\_\_\_ \_

Intake was: (Circle one)

- 1 Typical
- 2 Considerably more than usual
- 3 Considerably less than usual

Information was: (Circle one)

- 1R
- 2UTR
- 3UR

Intake day/s: 1 Sunday 4 Wednesday 6 Friday  
2 Monday 5 Thursday 7 Saturday  
3 Tuesday

Collection method: (Circle one)

- 1 Recall
- 2 Record

Visit #: \_\_\_\_ \_

**To be completed by TNDC:**

Date coded: \_\_\_\_ - \_\_\_\_ - \_\_\_\_  
                  m m d d y y

Date Checked: \_\_\_\_ - \_\_\_\_ - \_\_\_\_  
                  m m d d y y

Coder ID#: \_\_\_\_ \_


Checker ID#: \_\_\_\_ \_

Form - N-1  
c 1995

**F. MANUAL OF OPERATIONS (MOOP)**

# MENOPAUSAL SYMPTOMS STUDY

## MANUAL OF OPERATIONS



# Effect of a Soy Dietary on Menopausal Symptoms and Hormones in Women at High Risk of Breast Cancer (MSS)

## ROSTER

### Tufts University School of Medicine

<u>Name</u>	<u>Position</u>	<u>Telephone</u>	<u>TELEFAX</u>
Margo Woods, D.Sc. <sup>1</sup>	Principal Investigator	617-636-0809	617-956-5810
Ann LaBrode, MS, RD <sup>1</sup>	Project Coordinator	617-636-0810	617-956-5810
Sherwood L. Gorbach, MD <sup>2</sup>	Division Chair	617-956-5811	617-956-5810
Barry Goldin, Ph.D. <sup>3</sup>	Biochemist	617-956-5814	617-956-5810
Lisa Gualtieri <sup>3</sup>	Laboratory Supervisor	617-636-0811	617-956-5810
 Susan Sajer, MD <sup>4</sup>	 Emerson Hospital	 508-287-3436	 508-287-3642

Department of Community Health<sup>1</sup>  
 Tufts University School of Medicine  
 Room Stearns 203  
 136 Harrison Avenue  
 Boston, MA 02111

Emerson Hospital<sup>4</sup>  
 John Cuming Boulevard  
 Suite 110  
 Concord, MA 01742

Room Arnold 204<sup>2</sup>  
 Room Stearns 324<sup>3</sup>

### Sloan Kettering

<u>Name</u>	<u>Position</u>	<u>Telephone</u>	<u>TELEFAX</u>
Ruby Senie, Ph.D. <sup>5</sup>	Principal Investigator, Sub	212-639-2373	212-794-5812
Patrick Borgen, MD	Co-Investigator		
	Biostatistician		
Guang-Youe Lee	Data Manager		
Fredi Kronenberg <sup>6</sup>	Consultant	212-305-2009	212-305-1495

Memorial Sloan Kettering Hospital<sup>5</sup>  
 1275 York Avenue  
 New York, New York 10021

Columbia University<sup>6</sup>  
 College of PNS  
 630 West 168th Street  
 New York, New York 10032

## 2. INTRODUCTION

### a. Overview of Manual

This manual describes operations at Tufts University School of Medicine and Memorial Sloan Kettering Hospital for the Menopausal Symptoms Study (MSS) funded by the United States Army under the title "Effect of a Soy Dietary on Menopausal Symptoms and Hormones in Women at High Risk of Breast Cancer". It details those operations that should be performed in a standardized fashion at both sites and includes all study protocols.

### b. Data Forms

The following numbered forms will be used to collect participant data.

<u>Form</u>	<u>Description</u>
F1	Screening Questionnaire (probably for Boston only)
F2	Menopausal Symptoms Questionnaire
F3	Medical History Form (completed by ppt in Boston, transferred to form by staff in NYC.
F4	Study Log
F5	Seven Day Daily Symptoms Diary
N1	Food Record/Instructions
N2	Food Questionnaire

Once a patient has been randomized into MSS and assigned a study ID number a folder (or notebook) must be initiated. Paper copies of all numbered forms, laboratory results and study booklets should be filed in the participants folder. MSS forms for all patients screened but not enrolled must also be retained. These do not need to be filed in individual folders, however, should be kept together.

### i. Study ID's

#### **Intervention**

Intervention Women will be assigned sequential numerical ID's according to the following scheme. Dropouts must be reported to Sloan Kettering in order to maintain the appropriate randomization scheme.

Tufts: ID 's 001-200  
NYC: ID's 201-399

#### **Control:**

Tufts: ID's 500-599  
NYC: ID's 600-799

**c. Schedule of Study**

**i. Time Line**

Months

0 to 4	Development and printing of questionnaires Development of data entry forms Development of recruitment materials (letters, flyers, advertisements) Training of study recruiters Write Manual of Operations (MOOP)
5-40	Recruit subjects Begin study Collect and analyze study data serum urine dietary
42-48	Complete laboratory studies Statistical analyses Write final report

### 3. RECRUITMENT, SCREENING AND ENROLLMENT

#### a. Overview

All subjects must go through the screening process in order to determine eligibility for their study. The initial screening may take place either over the telephone using the Telephone Screening Questionnaire (F1) or in the clinic. As part of the screening participants must complete the Menopausal Symptoms Questionnaire (F2), Medical History Form (F3) and Seven Day Daily Symptoms Diary (F5).

#### b. Screening Process

##### Initial Screen to take place over the Telephone or at the Clinic

1. Introduction/Purpose of Study/Screening Process
2. Complete Screening Questionnaire (F1)
3. If the person is ineligible thank them for their interest in the study. If the person may be eligible ask them if you can send/give them some forms to complete to determine complete eligibility. Explain the forms to be completed and ask the participant to mail them all back after the Seven Day Daily Symptoms Diary is completed.
4. Mail or give to participant
  - a. Introductory Letter
  - b. Menopausal Symptoms Questionnaire (F2)
  - c. Medical History Questionnaire (F3)
  - d. Seven Day Daily Symptoms Diary (F5)
  - e. Food Questionnaire (N2).
  - f. Consent Form 1 (Screening)
  - g. Self addressed Stamped envelope
5. Review the returned forms (F2, F3, F5) questionnaires for eligibility. (If the participant has not returned the forms within 2 weeks call to see if they have mailed forms or are still interested).
  - a. Ineligible: Send a form letter (L1) to the participant thanking them for their interest.
  - b. Potential: Determine if participants are eligible for either the control or intervention group. If they are not eligible for either one send them a form letter (L1). If they are eligible for the control group or intervention group call them, describe the study they are eligible for (control or intervention) and schedule a Screening/Baseline Visit (SBV1).



**c. General Eligibility Criteria**

Subjects: Subjects for this study will be postmenopausal women, ages 48-58 who are at high risk for breast cancer. A total of 200 women will be studied, 100 from Boston and 100 from NYC; from each clinic half of the women (n=50/clinic) will be control subjects who are without menopausal symptoms and half will be women who are experiencing frequent and consistent menopausal symptoms (hot flashes and night sweats). Women will be assigned to the control and intervention groups based on the frequency of hot flashes and night sweats as ascertained by the menopausal questionnaire. Those with  $\geq 5$  hot flashes during a 24 hour period will be eligible for the intervention arm of the study. Women with less than one hot flash/night sweat per day will be eligible for the control group.

*The terms hot flash, hot flush and night sweats are considered to be the same. These are typically sudden episodes of feeling warm, flushing and/or sweating. These events can take place during the day or night.*

Eligibility: Women at high risk for breast cancer as defined by having one or more of the following characteristics: 1) mother or sister with breast cancer, 2) two or more benign breast biopsies, 3) one breast biopsy with diagnosis of proliferative breast disease. Women who have undergone a natural menopause (no periods for at least one year) will be eligible. Women recruited must be within 90-120% of ideal body weight.

**d. Exclusion Criteria**

Exclusions: Women will be excluded for the following reasons:

1. surgical menopause (no intact ovaries)
2. Use of HRT within the last 6 months.
3. previous breast cancer
4. history of frequent use of antibiotics (>2 times per year).
5. high intake of soy products such as tofu, soybeans, soy flour
6. medications that effect or interfere with hormone metabolism including the following classes of drugs (**expand this list**)
  - Antibiotics
  - Hepatic enzyme inducers i.e. phenobarbital, dilantin, rifampin
  - Hepatic enzyme inhibitors i.e. cimetidine, zantac, tagamet
  - Prostaglandin inhibitors i.e. aspirin
  - Steroids/Hormones i.e. prednisone
  - Antacids
  - Tricyclic antidepressants
  - Blood thinners i.e. coumadin, warfarin

**e. Recruitment**

**i. Tufts**

Letters will be sent to all age-eligible, high breast cancer risk patients from the Breast Health Center (BHC) and Dept. of OB/GYN at New England Medical Center Hospital (see sample). Included in the proposal are letters of support from the director of the BHC and the chief of OB/GYN to recruit from their patient populations. A trained recruiter will be available at the clinic site 3 half-days a week (during the scheduled clinic times). Dr. Sajer, will be involved in overseeing the clinic recruitment protocol in the BHC and OB/GYN clinics. Advertisements will be placed in the NEMCH newsletter and local newspapers. Letters will be sent to all OB/GYN physicians in the greater Boston area. Copies of all advertisements/posters must be submitted to the NEMCH HIRC for approval.

**ii. Sloan Kettering**

Women will be recruited from the Special Surveillance Breast Program and from the Breast Diagnostic and Treatment Center at Memorial Sloan Kettering Cancer Center.

**f. Enrollment**

Enrollment will take place at the Screening/Baseline Visit 1 (SBV1). A participant is enrolled when she is assigned a study identification number. To ensure that the participant is enrolled corresponding to the preassigned randomization sequence, the next available study identification number must be selected from the Randomization List and the randomization list must be appropriately updated. Verify eligibility for the control or intervention group and have participant sign the appropriate consent forms.

**g. Randomization**

A randomization list will be developed by the biostatistical office at Memorial hospital. Random assignment will be made using a computer algorithm to ensure a balanced assignment for every 10 patients entered, and will take into account patient dropout. Dietary supplement bars will be labelled and pre-packaged at Tufts University and these efforts will be supervised by Lisa Gualtieri, Laboratory Manager. All study personnel will be blinded as to assignment of soy or placebo bars.

## 4. STUDY PROTOCOL

### a. Overview

The purpose of this seven month study is to determine the effect of a soy dietary supplement bar on menopausal symptoms in women at increased risk for breast cancer who are experiencing frequent menopausal symptoms.. Women will be randomized using a double-blind, cross-over design to receive either a placebo bar or a soy dietary supplement bar for three months with a one month washout between protocols. A matched group of control women at high risk for breast cancer but with low symptomatology will be studied.


Intervention Group: Baseline blood and urine collections will be done on all women. At the two baseline visits SBV1 and BV2 blood samples will be taken (40 ml/SBV1, 30 ml/BV2) for measurement of routine blood chemistries and hormone levels and a first morning urine sample will be collected on the day of BV2. During Phase I, women are randomly assigned to either the soy supplement group or placebo group for three months. Subjects consume two soy or placebo bars each day. At the end of Phase I blood samples are taken on two days approximately one week apart (V3 and V4) and a first morning urine sample is collected on the morning of V4. During the fourth month of the study Phase II (Washout) women do not consume any supplement bars. For the remaining three months of the study (Phase III) women who were given the soy bar are switched to the placebo bar and women who were given the placebo are switched to the soy bar. At the end of the study blood and urine data are be collected as before at visits FV6 and FV7. The length of the dietary intervention study is 7 months.

Dietary data is collected at baseline, and at the end of Phases I, II and III. At baseline a food frequency questionnaire (N2) will be completed; this takes approximately 20 minutes. A three day food record (N1) will be kept at baseline, and at the end of Phases I, II and III. This requires that a subject write down all food and beverages consumed during a three day period and takes approximately 10-20 minutes each day. Subjects will receive instructions on how to keep a food record, and will review each completed food record with the as certified dietary data collector.

Throughout the study subjects record information about their menopausal symptoms. A menopausal symptoms questionnaire (F2) is completed at baseline and at the end of each phase. Women keep a daily study log to record the number of hot flashes they experience each day, and to track dietary supplement bar consumption. Also, at baseline and at the end of each phase, women keep a detailed seven day diary indicating the time and intensity of each hot flash experienced during a specified seven day period.

Control Group: Blood samples are taken on two days approximately 1 week apart SBV1 and CV2 (40 ml/SBV1 and 30 ml/CV2) for measurement of routine blood chemistries and hormones, and first morning urine samples will be collected on the day of CV2 for measurement of phytoestrogens. Women keep a daily diary of symptoms (hot flashes/night sweats) during this time. Dietary intake data is collected using a food frequency questionnaire and a three day food record.

## Study Overview-Flow Chart



**c. Distribution of Soy Dietary Supplements**

Dietary supplement bars are packaged in one 4 week supplies (56 bars) and distributed to participants monthly at regularly scheduled study visits and mailed to participants at home between visits.

**d. Collection of Study Data**

**i. Blood Samples**

Intervention Group: Blood samples are required at SBV1, BV2, V3, V4, FV6 and FV7.

Control Group: Blood samples are required at SBV1 and CV2,

**ii. Urine Specimens**

Intervention Group: At BV2, V4 and FV7 subjects will provide a specimen from the first morning void .

Control Group: At CV2 subjects will provide a specimen from the first morning void .

If the participant forgets to collect the first morning void a specimen is collected at the time of the visit.

**ii. Food Records (N1)**

Intervention Group: Three day food records are kept at baseline, and at the end of Phases I, II and III.

Control Group: One three day food record is kept at baseline.

At the Screening/Baseline Visit **SBV1** participants are given specific instructions on how to keep a three day food record by study personnel who have been trained and certified in dietary assessment for this study. Participants are provided with a scale to assist them in recording accurate amounts of food consumed.

**iii. Seven Day Daily Symptoms Diary (F5)**

This booklet is used to record the time and intensity of all hot flashes experienced during a specified period. The seven day daily symptoms diary is kept by all participants as part of the screening process to determine eligibility for the control or intervention group.

Control Group: The seven day daily symptoms diary is kept during the first week of the study.

Intervention Group: The seven day daily symptoms diary is kept at baseline and at the end of Phases I, II and III.

#### **iv. Study Log (F4)**

The Study Log is used only by the women in the intervention group. Each day throughout the study women record the number of hot flashes experienced during waking and sleeping hours and indicate the number of soy bars eaten. Subjects are given a new study log each for each month of the study and at the end of each month should mail the completed study log to the study coordinator at each clinic.

## 5. LABORATORY PROCEDURES

### a. Collection of Blood

Blood samples are required at SBV1, V2, V3, V4, V6 and FV7.

#### i. Collection Tubes/Supplies

Blood will be collected in 10 ml SST red top vacutainers . Serum will be stored in 17x100mm polystyrene tubes and 17 x100 mm tubes 1/out caps will be needed for processing.

Supplies can be ordered from local scientific supply companies. The items needed are described in the Fisher Scientific catalog as described below:

<u>Item</u>	<u>Description</u>	<u>Catalog#</u>	<u>Price</u>
SST Serum Separation Tube Red stopper lubricated w/silicone	B-D No. 367815 13x100	02-683-94	Case of 1000/ \$252.40
Sterile Plastic tubes with snap caps	17x100	14-956-6A	Case of 1000/ \$135.50
Sterile Plastic tubes w/out caps	17x100	14-956-6C	Case of 1000/ \$90.00

#### ii. Procedures for Obtaining Specimens

All blood samples will be obtained by venipuncture. At SBV1 one 10 ml red top tube (SST) will be taken and sent to clinical chemistry for routine blood chemistry analyses blood and three 10 ml red top SST (serum separator tubes) will be taken for hormone analyses. At all subsequent visits three 10 ml red top SST (serum separator tubes) will be taken for hormone analyses.

Boston: Blood samples will be taken by licensed phlebotomists at the Blood Drawing Laboratory located in the South building. Subjects will either transport the blood to our laboratory or study personnel will accompany the participant to Blood Drawing and then take the sample to our Laboratory for processing and storage . Study personnel will take Universal Precautions when handling and/or transporting blood samples.

New York City: Blood samples will be taken by licensed phlebotomists or trained personnel in the outpatient area and then processed in the laboratory. Study personnel will take Universal Precautions when handling and/or transporting blood samples.

### iii. Processing of Blood

Serum specimens should be processed as follows:

1. Allow tubes to sit for 20-30 minutes (but no longer than 2 hours) in a test tube rack.
2. With the cap in place, centrifuge at 2500 RPM for 5 minutes. (Tufts use the Beckman tabletop centrifuge set at speed 6.8 brake set on high. Centrifuge must be balanced prior to spinning.
3. Pour serum from all three tubes into one plastic 17x100 mm tube, Serum is aliquoted by pipette as follows:
  - a.. 5.0 ml is put into a 17 x 100 mm tube for hormone analyses by Dr. Longcope.
  - b. 5.0 ml is put into a 17 x 100 mm tube for storage at Tufts.
  - c. Remaining serum is measured and put into a 17 x 100 mm tube for storage.

#### (1) Labelling of Samples

Labels will be preprinted for each subject. *Check to be sure that the subject ID and visit number on the label correspond to the patient who had blood drawn.* It is necessary for the clinic to record the date on each label. Also, the ml of remaining serum must be written in on Tube #3. After labels are placed on polystyrene tubes they must be secured by clear "non-temperature sensitive" tape to the tube. This is extremely important because the laser printer labels will not adhere properly to the tubes in the freezer.

If the preprinted labels are lost or damaged the following information must be written clearly on the tube, following the same format as the preprinted labels.

Study Name	=	MSS in the upper left hand corner,
Site	=	BOS (Boston), NYC (New York City) next to
Sample ID	=	Subject ID ### - Visit - Sample Number
		Subject ID: Boston 001-200, NYC 201-399
		Visit: SBV1,BV2,V3,V4, FV6,FV7
		Sample #: 1,2,3,4,5,6
Date of sample	=	MM/DD/YY in the lower left corner
Serum Identifier	=	Serum Hormones or Serum Storage in the upper right hand corner
Tube Number	=	1,2,3
Amount of serum	=	amount in ml in lower right hand corner



EXAMPLE:

A set of labels for subject 1 from Boston taken at visit SBV1 on 1/1/95 would look like this:

MSS-BOS	Serum Hormones	MSS-BOS	Serum Storage	MSS-BOS	Serum Storage
001-SBV1-1	1	001-SBV1-1	2	001-SBV1-1	3
Date <u>1/1/95</u>	5.0 ml	Date <u>1/1/95</u>	5.0 ml	Date <u>1/1/95</u>	___ ml

**(2) Laboratory Sample Log Books/Storage Boxes**

Each tube is logged into the laboratory Sample Log Book. For each sample the following information is entered in the LOG, Study ID, Visit, Sample #, Date, Tube #, ml of blood, and Storage Box # and comments indicating any problems or anything unusual about the sample.

Study logs will be entered into PARADOX at each clinic on a weekly basis.

EXAMPLE:

**MSS STUDY- BOSTON  
SERUM LOG**

ID	Visit	Sample#	Date	Tube#	Amount	Box	Comments
001	SBV1	1	1/1/95	1	5.0	H01	serum clot
001	SBV1	1	1/1/95	2	5.0	S01	serum clot
001	SBV1	1	1/1/95	3	7.5	S01	serum clot

At each clinic there will be two sets of storage boxes- those for tubes labelled Serum Hormones and those for tubes labelled Serum Storage. The Storage boxes are labelled on the outside with the following information, Study Name, Clinic, Box Title (Serum Hormones/Serum Storage) and Box #. Box #'s should be in consecutive, numerical order, for example, H01, H02,... S01, S02...

MSS-BOS	Hormones
Serum	Box H01

MSS-BOS	Storage
Serum	Box S01

Storage boxes and dividers for storing the serum tubes can be ordered from Fisher Scientific:

<u>Item</u>	<u>Revco #</u>	<u>Catalog No.</u>	<u>Price</u>	<u>Number/Clinic</u>
Box	5956	11-678-24B	Package of 12/\$28.00	~ 2 packages
Dividers	5959	11-678-26D	Package of 12/\$15.00	~ 2 packages

#### **iv. Problems with Handling Blood Specimens**

Reliable tests can only be obtained from properly collected specimens. Some common problems are:

1. Hemolysis; Blood which is hemolyzed during collection may interfere with some analyses. Hemolysis may be caused by overcentrifugation, excessive shaking of the sample, freezing cells and forcing blood through the venipuncture needle.
2. Hemoconcentration: If the tourniquet is left on too long during venipuncture, stasis may occur in the vein and blood constituents may be more concentrated than normal.
3. Overcentrifugation: Blood specimens should be centrifuged only after standing for 20-30 minutes to allow clotting to occur. Centrifugation should be gentle to avoid cell damage and serum should be separated as soon as possible from the cells. A serum separator in the tube physically separates the serum from red blood cells.
4. Evaporation: Blood and urine samples should remain capped until the time of testing to prevent evaporation. Evaporation can alter pH or  $\text{HCO}_3$  and cause concentration.
5. Contamination: To avoid contamination or dilution, clean dry pipettes should be used to aliquot each specimen.
6. Thawing: Freezers should be monitored daily for temperature drift since large temperature swings affect samples adversely.

#### **v. Storage of Blood**

Serum tubes are stored in storage boxes at  $-70^\circ\text{C}$  and should be frozen immediately.

#### **vi. Shipment of Blood**

Blood should be shipped to Tufts approximately every 3 months.

#### **vii. Shipping Logs**

A separate shipping log must be included for each box of serum.

#### **viii. Packing the Specimens**

Specimens should be packed in enough dry ice to last 24 hours. The shipping logs should be placed in a plastic zip loc bag inside the box or in an envelope on the outside of the box.

## **ix. Shipping Procedures**

Bloods should be shipped using an overnight delivery service that guarantees delivery before noon. Samples should only be shipped Monday-Wednesday. Prior to shipping it is imperative that a representative from Tufts be contacted (Ann LaBrode, Christina Sadlow, Margo Woods or Lisa Gualtieri) to be sure that someone will be there to check on arrival of samples.

## **x. Analysis of Samples (Tufts/NYC)**

All hormones determinations will be done in the laboratory of Dr. Christopher Longcope at the University of Massachusetts Medical School. As described blood samples are collected on two days (approximately one week apart) at baseline and at the end of Phases I and III. Pooled serum samples from the two days are used for hormone analyses. Serum hormone measurements are carried out for estrone, estradiol, free estradiol, estrone sulfate, androstenedione and testosterone by radioimmunoassay involving solvent extraction and celite chromatography. All samples are run in duplicate. The FSH determinations are performed by a double-antibody radioimmunoassay utilizing a kit obtained from Radioassay Systems Laboratories Inc., Carson CA.

## **xi. Quality Control Procedures**

Blinded duplicate quality control samples will be sent to Dr. Longcope's laboratory for analysis and a quality control report will be written.

### **a. Collection of Urine**

#### **i. Collection Bottles/Supplies**

Urine will be collected in 4 oz/118 ml specimen collection containers and stored in 30 ml polyethylene sample bottles. Supplies can be ordered from local scientific supply companies and are described in the Fisher Scientific catalog as indicated below:

<u>Item</u>	<u>Description</u>	<u>Catalog Number</u>	<u>Price</u>	<u>Number/Clinic</u>
4 oz./118ml Specimen container	Non-sterile/ white cap	14-375-148	Case of 500/ \$96.50	~ 1 case
Nalgene* Transculent high density polyethylene cap 28mm storage bottles	1 oz/30 ml	03-313-4A Nalge 2189-0001	Case of 72/ \$64.20	~600/9 cases

## ii. Procedures for Obtaining Specimens

At SBV1, V3 and FV6 each participant should be given an instruction sheet and a small container for the collection of a first morning voided urine specimen on the mornings of BV2, V4 and FV7. It is not necessary to collect the entire first morning void, only a sufficient volume (e.g., 100 ml) for the required urine aliquots. The sample should be collected before the participant eats or drinks anything. The container should have a label marked with the Study ID, Visit number for urine collection, urine collection number (1,2,3) and date of urine collection. In addition the time of the collection should be recorded on the label. The specimen should be kept refrigerated or cold until it is turned in at the clinic.

**Important:** Prior to the urine collection 0.1 grams of ascorbic acid powder must be added to each urine collection container. This prevents the breakdown of the urinary phytoestrogens.

## iii. Processing of Urine

Specimens should be stored in the refrigerator until they can be processed. Specimens must be processed within 24 hours. Processing should follow these steps:

1. Mix urine well to suspend sediment.
2. Aliquot 30 ml of urine into each of the three urine storage bottles.
3. Add 0.3 ml of 10% Sodium Azide solution to each 30 ml aliquot. (10% Sodium Azide solution is prepared by mixing 10 g of Sodium Azide w/100 ml water).
4. Samples are stored at -70° until shipment to Tufts.

## iv. Labelling of Samples

Labels will be preprinted for each subject. *Check to be sure that the subject ID and visit number on the label correspond to the patient who brought in the urine sample.* It is necessary for the clinic to record the date on each label. After labels are placed on the storage bottles they must be secured by clear "non-temperature sensitive" tape to the tube. This is extremely important because the laser printer labels will not adhere properly to the tubes in the freezer.

Study Name	=	MSS in the upper left hand corner,
Site	=	BOS (Boston), NYC (New York City) next to
Sample ID	=	Subject ID ### - Visit - Sample Number
		Subject ID: Boston 001-200, NYC 201-399
		Visit: BV2,V4, FV7
		Sample #: 1,2,3
Date of sample	=	MM/DD/YY in the lower left corner
Urine Identifier	=	the word "Urine" in the upper right hand corner
Bottle Number	=	1,2,3
Amount of urine	=	amount in ml (30) in lower right hand corner

A set of urine labels for subject 1 from Boston for a urine collection done on BV2 on 1/7/95 would look like this:

MSS-BOS	Urine/Phytoes
001-BV2-1	1
Date <u>1/7/95</u>	30 ml

MSS-BOS	Urine Creat
001-BV2-1	2
Date <u>1/7/95</u>	30 ml

MSS-BOS	Urine Storage
001-BV2-1	3
Date <u>1/7/95</u>	30 ml

Each Bottle is logged into the laboratory Sample Log Book. For each sample the following information is entered in the LOG, Study ID, Visit, Sample #, Date, Bottle #, ml of urine, and Storage Box # and comments indicating any problems or anything unusual about the sample. Study logs will be entered into PARADOX at each clinic on a weekly basis.

## MSS STUDY- BOSTON

### URINE LOG

ID	Visit	Sample#	Date	Bottle#	Amount	Box	Comments
001	SBV1	1	1/1/95	1	5.0	P01	
001	SBV1	1	1/1/95	2	5.0	C01	
001	SBV1	1	1/1/95	3	5.0	S01	

At each clinic there will be three sets of storage boxes- those for bottles labelled "Urine Phytoes", those for bottles labelled "Urine Creatinine" and those for bottles labelled "Urine Storage". The Storage boxes are labelled on the outside with the following information, Study Name, Clinic, Box Title (Serum Hormones/Serum Storage) and Box #. Box #'s are in consecutive, numerical order, and the box number is preceded by a P for Phytoes, C for Creatinine or S for Storage, for example:

MSS-BOS Urine	Phytoes Box P01
------------------	--------------------

MSS-BOS Urine	Creatinine Box C01
------------------	-----------------------

MSS-BOS Urine	Storage Box S01
------------------	--------------------

**iv. Storage of Urine**

Urine is stored in the freezer at -70° .

**vi. Shipment of Urine**

Urine should be shipped to Tufts approximately ever 3 months.

**vii. Shipping Logs**

A separate shipping log must be included for each box of urine

**viii. Packing the Specimens**

Specimens should be packed in enough dry ice to last 24 hours. The shipping logs should be placed in a plastic zip loc bag inside the box.

**ix. Shipping Procedures**

Urine should be shipped using an overnight delivery service that guarantees delivery before noon. Samples should only be shipped Monday-Wednesday. Prior to shipping it is imperative that a representative from Tufts be contacted (Ann LaBrode, Christina Sadlow, Margo Woods or Lisa Gualtieri) to be sure that someone will be there to check on arrival of samples.

**x. Analysis of Samples (Tufts)**

Phytoestrogens will be analyzed in the laboratory of Dr. Herman Adlercreutz with whom our group has collaborated for over 15 years. The phytoestrogens to be measured are matairesinol, secoisalariciresinal, enterolactone, enterodiol, genestein, daidzein, equol and o-desmethylangolensin). Urine samples will be collected from intervention women at baseline and at the end of Phase I and Phase III. While urine samples will be collected on all intervention women, at this time only 25% of the population will be analyzed due

to the high cost of the analyses. The remaining samples will be stored and additional funding will be sought.

The determination of the urinary lignans and phytoestrogens will allow us to: 1) validate baseline intake of these compounds. 2) verify compliance with the dietary supplement protocol and 3) correlate symptoms with urinary excretion of these individual compounds. From each urine sample 0.33% of the sample is used for analysis. The urine is buffered by adding 1.5M acetate buffer pH3.0. The volume of buffer added is 10% of the urine volume.  $^3\text{H}$ -estrone glucuronide (10,000 DPM) is added as an internal standard to correct for losses during the analysis procedure.

Sep-Pak C<sup>18</sup> extraction: Before use, the Sep-Pak column is washed with 5 ml of methanol and 10ml water. The urine sample is added and the column is washed with 5 ml of 0.15 M acetate buffer pH 3.0 and the column is eluted with 3 ml of methanol. To the methanol eluate a total of 1.2 ml of water is added. The 4.2 ml sample is added to a DEAE-Ac- column which has been prepared in a pasteur pipette in 70% methanol. The column is eluted by adding 4 ml of 70% methanol. This fraction is discarded. The final elution is performed with 10 ml of 0.3 M LiCl in 70% methanol. This fraction contains the conjugates of the lignans and phytoestrogens. Because the amount of free lignans and isoflavones is negligible only the final elute is used for further analysis. The deuterated internal standards enterolactone, enterodiol, matairesinol, equol, daidzein O-desmethylangolensin and genistein are added. The methanol is then evaporated off leaving only the water. To this specimen additional water is added to make a total volume of 10 ml and then 1 ml of 1.5 M acetate buffer, pH 3.0 is added. The sample is transferred to a Sep-Pak column that has been previously washed with 5 ml of 0.15 M acetate buffer pH 3.0. The sample is then eluted with 3 ml of methanol and the eluate is evaporated to dryness.

Hydrolysis of the conjugates: 5 ml of 0.15 M acetate buffer pH 4.1 containing 25 mg ascorbic acid and 500 ul of Helix Pomatra (Sigma Chemical Co., St. Louis) enzyme extract is added to the evaporate. The sample is incubated for 12 hours at 37°C.

Separation of free lignans and phytoestrogens: The sample is added to washed (5ml water) Sep-Pak column and eluted with 3 ml of methanol. The eluate is added to a QAE-A column. The column is first eluted with 4 ml of methanol. This fraction #1 contains enterolactone, enterodiol, matairesinol, equol and estrogens. The second fraction (fraction #2) is eluted from QAE-Ac column by adding 7 ml of 0.2 M acetic acid in methanol (1:85 v/v). Fraction #2 contains o-desmethylangolensin (DAM), daidzein (DA) and genistein (ge). Fraction #1 is evaporated to dryness and 4 ul ml methanol and 0.1 ml water are added to the residue. The sample (0.5ml) is added to a QAE-Ac column (4 x 0.5 cm). The column is initially eluted with 4 ml of 80% methanol and this fraction containing the estrogens is discarded. The column is then eluted with 5 ml 0.1 M acetic acid in methanol: water (4.1). This fraction contains enterolactone, enterodiol, equol and matairesinol.

Analysis for lignans and phytoestrogens: Fractions #1 containing lignans plus equol (isoflavone) or fraction #2 containing isoflavones are separated by evaporating the fractions to dryness and adding 100 ul of pyridine/HMDS/TMS (9:3:1) and incubating for 30 minutes at room temperature. The fractions are then evaporated to dryness and residue is dissolved in 100-300 ul of hexane.

The fractions in hexane are then analyzed by GC/MS as previously described (45). The identification of each compound is based upon its gas chromatographic retention time on two capillary columns of different polarity, the complete mass spectra and selection ion monitoring responses relative to the authentic standards. The quantification is achieved by relating the peak areas of the specimen to the peak area of known amounts of the internal standards.

#### **xi. Quality Control Procedures**

Blinded duplicate samples will be sent and analyzed for a measure of quality control.

#### **c. Universal Precautions for Handling Biological Specimens**

Biological specimens may contain infectious agents which may be harmful to specimen handlers. The CDC strongly recommends universal blood and body fluid precautions when handling all patient specimens. These include:

1. Use of protective barriers to prevent exposure of skin or mucous membranes, including gloves, goggles or safety glasses. These should be disposed of properly after use.
2. Hands should be washed immediately after removing gloves, and any contaminated skin surface should be washed immediately and thoroughly.
3. Use precautions to avoid injuries from sharp, contaminated instruments such as needles.
4. Do not contaminate the outside of specimen containers, labels or forms.
5. Never pipet by mouth. Only pipets with safety bulbs or automatics pipets should be used.
6. Biological specimens and contaminated articles including blood tubes and pipets must be placed in a special biohazard bag for disposal.
7. The lab work area should be disinfected before and after use and whenever a spill occurs. An appropriate solution is a 5-10% solution of sodium hypochlorite or a good commercial lab disinfectant.



### 3. Soy Bars

The Soy and Placebo bars are produced by Protein Technologies and have the following nutrient composition.

	Soy Bar	Placebo Bar
Serving (g)	65.0	56
Moisture (g)	6.5	6.7
Fat (g)	1.3	0.9
Protein (g)	15.1	16.4
Ash (g)	2.0	2.1
Carbohydrate (g)	31.1	29.9
Calories (kcal)	196.	194
Calcium (mg)	711.	497
Iron (mg)	4.0	2.1
Phosphorous (mg)	502	304
Sodium (mg)	168	106
Folic Acid (mcg)	142	158
Pantothenic Acid (mg)	.94	.78
Vitamin B6 (mg)	.26	.23
Riboflavin (mg)	.45	.35
Thiamin (mg)	.23	.14
Vitamin A (IU)	668	809
Vitamin B12 (mcg)	1.29	3.19
Vitamin C (mg)	1.41	1.67
Vitamin D (IU)	153	164

**G. CONSENT FORM - TUFTS**

Tufts University School of Medicine  
New England Medical Center Hospital

**CONSENT FORM 1 (Screening)**

**Menopausal Symptoms Study**

**Principal Investigator: Margo N. Woods, D.Sc.**

**Medical Monitor: Sherwood L. Gorbach, M.D.**

**Purpose:** The purpose of this research study is to investigate the effect of dietary soy on hormone levels and menopausal symptoms in women at increased risk for breast cancer. This study is funded by the United States Army Medical Research, Development, Acquisition and Logistics (USAMRDL) Command (Provisional). This Study will be conducted at the Breast Health Center located in the South Building at New England Medical Center, 750 Washington Street. Boston, MA 02111.

**Rationale:** Menopausal symptoms have been associated with the decreased hormone levels that occur during menopause. Hormone replacement therapy (HRT) is given to approximately 30% of women in early menopause to alleviate some of the common symptoms experienced during menopause. While there are reported benefits of HRT on cardiovascular disease, osteoporosis, and menopausal symptoms there are concerns about the affect of HRT on breast cancer. Some studies have suggested that higher hormone levels may result in increased breast cancer risk.

Phytoestrogens are estrogen-like compounds found in plant products and high fiber foods including whole grains, legumes (especially soy) and some seeds. An increase in intake of soy products may contribute to the low incidence of breast and prostate cancer observed in Japanese women and men respectively. In addition, dietary soy has been shown to be inversely associated with breast cancer risk in Singapore. The relationship between soy and these cancers may be related to the phytoestrogens found in soy products, thus, it is possible that soy products may have an affect on hormone related, menopausal symptoms.

**Eligibility/Study Requirements:** To determine eligibility for this study you will be asked to complete a medical history questionnaire, a menopausal symptoms questionnaire, a one week daily diary of hotflashes/night sweats and a food frequency questionnaire. If you are eligible and agree to participate in this study a screening/baseline blood sample will be taken (40 ml -approximately 4 tablespoons) and analyzed for routine blood chemistries and hormone levels. This screening visit will take approximately 2 hours. Based on the results of the menopausal symptoms questionnaire and the daily diary of hot flashes you will be eligible for either the control group or the intervention group. If you are assigned to the control group you will be asked to participate in a one week study and baseline data will be collected as described in Consent Form 2. If you are assigned to the intervention group you will be asked to participate in a 7 month dietary intervention study as described in Consent Form 3.

\_\_\_\_\_  
Participant's Initial

\_\_\_\_\_  
Date

1

APPROVED: 12/13/94  
VALID THROUGH: 12/13/95

**Consent Form 1 (Screening)**

**Title:** Menopausal Symptoms Study      **Principal Investigator:** Margo N. Woods, D.Sc.

**Blood Drawing:** The total amount of blood to be taken for the screening is 40 ml.  
(approximately 3 tablespoons).

**Risks:** The only risks associated with this part of the study are those associated with blood drawing, which in rare cases results in an infection and occasionally in a black and blue mark. Blood drawing when performed by someone who has been specially trained and has experience in drawing blood decreases these risks.

**Benefits:** The data obtained in this study may be of no direct benefit to the participant but may yield insight into the effects of diet on hormone metabolism and its possible role in the cause and development of breast cancer.

**Whom to Contact:** If you have any questions about the study or experience any problems or injury or illness during it, you should call one of the following persons:

	Days	Evenings
Dr. Margo Woods	617-636-0809	617-646-6059
Dr. Sherwood Gorbach	617-636-5811	617-636-5111, beeper #1193

**Stipend:** Subjects will not be paid for participating in this initial screening. Stipends will be paid to Control and Intervention subjects as explained in Consent Forms 2 and 3. There will be no additional costs to the participant for participating in this study.

It is the policy of the U.S. Army Medical Research, Development, Acquisition and Logistics Command (Provisional) (USAMRDALC) that data sheets are to be completed on all volunteers participating in research for entry into the USAMRDALC's Volunteer Registry Data Base. The information to be entered into the data base includes your name, address, social security number, study name and dates. The intent of the data base is twofold: first, to readily answer questions concerning an individual's participation in research sponsored by the USAMRDALC; and second, to ensure that the USAMRDALC can exercise its obligation to ensure that research volunteers are adequately warned (duty to warn) of risks and to provide new information as it becomes available. The information will be stored at USAMRDALC for a minimum of 75 years. The computer data base will be kept confidential and not released to anyone.

APPROVED: 12/13/94  
VALID THROUGH: 12/13/95

Consent Form 1 (Screening)

Title: Menopausal Symptoms Study

Principal Investigator: Margo N. Woods, D.Sc.

PARTICIPANT'S STATEMENT

I have read this consent form and have discussed with Dr. \_\_\_\_\_ or his representative the procedures described above. I have been given the opportunity to ask questions, which have been answered to my satisfaction. I understand that any questions I might have asked will be answered verbally or, If I prefer, with a written statement understand that I will be informed of any new findings developed during the course of this research study.

I understand that my participation in this study is voluntary. I understand that I may refuse to participate in this study. I also understand that if, for any reason, I wish to discontinue my participation in this study at any time, I will be free to do so, and this will have no effect on my future care or treatment by my physicians or this hospital.

I understand that I am authorized all necessary medical care for injury or illness which is the proximate result of my participation in this research. Other than medical care that may be provided (and the stipend specifically stated in this consent form) there is no compensation available for my participation in this research study, however, I understand that this is not a waiver or release of my legal rights.

If I have any questions concerning my rights as a research subject in this study, I may contact the Human Investigation Review Committee at 617-636-7512. This office is located at 35 Kneeland Street, 6th floor Boston, MA 02111.

I have been fully informed of the above-described study with its risks and benefits, and I hereby consent to the procedures set forth above. I have received a copy of this consent form.

I understand that as a participant in this study my identity and my medical records and data relating to this research study will be kept confidential, except as required by law, and except for inspections by the study sponsor, the United States Army Medical Research, Development, Acquisition and Logistics (USAMRDL) Command (Provisional).

\_\_\_\_\_  
Participant Signature

\_\_\_\_\_  
Date

\_\_\_\_\_  
Participant name (printed)

\_\_\_\_\_  
Address (street or PO Box, city, zip code)

APPROVED: 12/13/94  
VALID THROUGH: 12/13/95

Consent Form 1 (Screening)

Title: Menopausal Symptoms Study

Principal Investigator: Margo N. Woods, D.Sc.

I have fully explained to \_\_\_\_\_ the nature and purpose of this above described study and the risks that are involved in its performance. I have answered all questions to the best of my ability.

\_\_\_\_\_  
Principal Investigator/Representative

\_\_\_\_\_  
Witness Signature

\_\_\_\_\_  
Witness Printed name

\_\_\_\_\_  
Date

APPROVED: 12/13/94  
VALID THROUGH: 12/13/95

Tufts University School of Medicine  
New England Medical Center Hospital

CONSENT FORM 2 (Control)

Menopausal Symptoms Study

Principal Investigator: Margo N. Woods, D.Sc.

Medical Monitor: Sherwood L. Gorbach, M.D.

**Purpose:** The purpose of this research study is to investigate the effect of dietary soy on hormone levels and menopausal symptoms in women at increased risk for breast cancer. This study is funded by the United States Army Medical Research, Development Acquisition and Logistics (USAMRDAL) Command (Provisional). This Study will be conducted at the Breast Health Center located in the South Building at New England Medical Center, 750 Washington Street, Boston, MA 02111.

**Rationale:** Menopausal symptoms such as hot flashes and night sweats have been associated with the decreased hormone levels that occur during menopause. Hormone replacement therapy (HRT) is given to approximately 30% of women in early menopause to alleviate some of the common symptoms experienced during menopause. While there are reported benefits of HRT on cardiovascular disease, osteoporosis, and menopausal symptoms there are concerns about the affect of HRT on breast cancer. Some studies have suggested that higher hormone levels may result in increased breast cancer risk.

Phytoestrogens are estrogen-like compounds found in plant products and high fiber foods including whole grains, legumes (especially soy) and some seeds. An increase in intake of soy products may contribute to the low incidence of breast and prostate cancer observed in Japanese women and men respectively. In addition, dietary soy has been shown to be inversely associated with breast cancer risk in Singapore. The relationship between soy and these cancers may be related to the phytoestrogens found in soy products, thus, it is possible that soy products may have an affect on hormone related, menopausal symptoms.

**Eligibility:** Based on the Menopausal Symptom Questionnaire you are eligible to participate in the Control Group for this study. This is because you are either not experiencing any hot flashes or you are not having hot flashes every day. The term "Control Group" is used because the purpose of the group is to collect data (blood hormones and urinary phytoestrogens) in order establish baseline data for this values in postmenopausal women with no menopausal symptoms or low levels of menopausal symptoms and to compare these values to women who are experiencing frequent menopausal symptoms.

Participant's Initial \_\_\_\_\_

Date \_\_\_\_\_

1

APPROVED: 12/13/94  
VALID THROUGH: 12/13/95

## Consent Form 2 (Control)

**Title:** Menopausal Symptoms Study

**Principal Investigator:** Margo N. Woods, D.Sc.

**Study Requirements:** If you choose to participate, the length of this study is approximately one week. During this week you will keep a three day food record and complete a one week daily diary of the number of hot flashes you have. Approximately one week after the screening visit a blood sample (30 ml) will be taken for measurement of hormones. On this morning you will be asked to collect all urine from your first morning void. You will be provided with a bottle for the collection, a cooler and ice pack. The urine must be kept cold until you come to the clinic.

**Blood Drawing:** The total amount of blood taken for this study will be 30 ml (approximately two tablespoons).

**Risks:** Blood drawing, in rare cases results in an infection and occasionally in a black and blue mark. Blood drawing performed by someone who is specially trained and experienced in blood drawing decreases these risks.

**Benefits:** The data obtained in this study may be of no direct benefit to the participant but may yield insight into the effects of diet on hormone metabolism and its possible role in the cause and development of breast cancer. Data from the blood analyses will be available to you.

**Whom to Contact:** If you have any questions about the study or experience any problems or injury or illness during it, you should call one of the following persons:

	<u>Days</u>	<u>Evenings</u>
Dr. Margo Woods	617-636-0809	617-646-6059
Dr. Sherwood L Gorbach	617-636-5811	617-636-5111 beeper #1193

**Stipend:** You will receive \$20 upon completion of the study. If you withdraw early from the study you will not receive any payment. There will be no additional costs to the participant for participating in this study.

It is the policy of the U.S. Army Medical Research, Development, Acquisition and Logistics Command (Provisional) (USAMRDALC) that data sheets are to be completed on all volunteers participating in research for entry into the USAMRDALC's Volunteer Registry Data Base. The information to be entered into the data base includes your name, address, social security number, study name and dates. The intent of the data base is twofold: first, to readily answer questions concerning an individual's participation in research sponsored by the USAMRDALC; and second, to ensure that the USAMRDALC can exercise its obligation to ensure that research volunteers are adequately warned (duty to warn) of risks and to provide new information as it becomes available. The information will be stored at USAMRDALC for a minimum of 75 years. The computer data base will be kept confidential and not released to anyone.

Participant's Initial \_\_\_\_\_

Date \_\_\_\_\_

2

APPROVED: 12/13/94  
VALID THROUGH: 12/13/95



**Consent Form 2 (Control)**

**Title: Menopausal Symptoms Study**

**Principal Investigator: Margo N. Woods, D.Sc.**

**PARTICIPANT'S STATEMENT**

I have read this consent form and have discussed with Dr. \_\_\_\_\_ or his representative the procedures described above. I have been given the opportunity to ask questions, which have been answered to my satisfaction. I understand that any questions I might have asked will be answered verbally or, If I prefer, with a written statement. I understand that I will be informed of any new findings developed during the course of this research study.

I understand that my participation in this study is voluntary. I understand that I may refuse to participate in this study. I also understand that if, for any reason, I wish to discontinue my participation in this study at any time, I will be free to do so, and this will have no effect on my future care or treatment by my physicians or this hospital.

I understand that I am authorized all necessary medical care for injury or illness which is the proximate result of my participation in this research. Other than medical care that may be provided (and the stipend specifically stated in this consent form) there is no compensation available for my participation in this research study, however, I understand that this is not a waiver or release of my legal rights.

If I have any questions concerning my rights as a research subject in this study, I may contact the Human Investigation Review Committee at 617-636-7512. This office is located at 35 Kneeland Street, 6th floor Boston, MA 02111.

I have been fully informed of the above-described study with its risks and benefits, and I hereby consent to the procedures set forth above. I have received a copy of this consent form.

I understand that as a participant in this study my identity and my medical records and data relating to this research study will be kept confidential, except as required by law, and except for inspections by the study sponsor, the United States Army Medical Research, Development Acquisition and Logistics (USAMRDAL) Command (Provisional).

\_\_\_\_\_  
Participant Signature

\_\_\_\_\_  
- Date

\_\_\_\_\_  
Participant name (printed)

\_\_\_\_\_  
Address (street or PO Box, city, zip code)

APPROVED: 12/13/94  
VALID THROUGH: 12/13/95

**Consent Form 2 (Control)**

**Title: Menopausal Symptoms Study**

**Principal Investigator: Margo N. Woods, D.Sc.**

I have fully explained to \_\_\_\_\_ the nature and purpose of this above described study and the risks that are involved in its performance. I have answered all questions to the best of my ability.

\_\_\_\_\_  
Principal Investigator/Representative

\_\_\_\_\_  
Witness Signature

\_\_\_\_\_  
Witness Printed name

\_\_\_\_\_  
Date

APPROVED: 12/13/94  
VALID THROUGH: 12/13/95

Tufts University School of Medicine  
New England Medical Center Hospital

**CONSENT FORM 3 (Intervention Group)**

**Menopausal Symptoms Study**

**Principal Investigator: Margo N. Woods, D.Sc.**

**Medical Monitor: Dr. Sherwood I. Gorbach, M.D.**

**Purpose:** The purpose of this study is to investigate the effect of dietary soy on hormone levels and menopausal symptoms in women at increased risk for breast cancer. This study is funded by the United States Army Medical Research, Development, Acquisition and Logistics (USAMRDAL) Command (Provisional). This Study will be conducted at the Breast Health Center located in the South Building at New England Medical Center, 750 Washington Street, Boston, MA 02111.

**Rationale:** Menopausal symptoms such as hot flashes and night sweats have been associated with the decreased hormone levels that occur during menopause. Hormone replacement therapy (HRT) is given to approximately 30% of women in early menopause to alleviate some of the common symptoms experienced during menopause. While there are reported benefits of HRT on cardiovascular disease, osteoporosis and menopausal symptoms there are concerns about the affect of HRT on breast cancer. Some studies have suggested that higher hormone levels may result in increased breast cancer risk.

Phytoestrogens are estrogen-like compounds found in plant products and high fiber foods including whole grains, legumes (especially soy) and some seeds. An increase in intake of soy products may contribute to the low incidence of breast and prostate cancer observed in Japanese women and men respectively. In addition, dietary soy has been shown to be inversely associated with breast cancer risk in Singapore. The relationship between soy and these cancers may be related to the phytoestrogens found in soy products, thus, it is possible that soy products may have an affect on hormone related, menopausal symptoms.

This 7 month dietary intervention study will use a random cross- over design to determine the effect of a soy dietary supplement on menopausal symptoms and endogenous hormones. The term "intervention" or "intervention group" means that something is being changed in order to see what affect it might have; in this study subjects will be asked to change their eating habits by eating a dietary soy supplement bar, in order to see whether the dietary soy supplement has any affect on hormones or menopausal symptoms. In Phase I of this study one group of subjects will be given the soy dietary supplement bar for the first three months of the study and the other group of subjects will be given a bar that is very similar to the dietary soy bar, except that it does not contain soy. (This bar is called the placebo bar because it is not anticipated that this bar will have any affect on hormone levels or menopausal symptoms.) The placebo bar will be identical in taste and appearance to the soy bar). For the next four weeks of the study (Phase II)

\_\_\_\_\_  
Participant's Initials

\_\_\_\_\_  
Date

1

### Consent Form 3 (Intervention)

**Title:** Menopausal Symptoms Study

**Principal Investigator:** Margo N. Woods, D.Sc.

participants will not consume any supplement bars. This period is called a washout. For the last three months of the study (Phase III) the group that received the soy bar in the first part of the study will be given the placebo bar and the group that received the placebo bar for the first part of the study will be given the soy bar. This type of study is called a cross-over study. Half of the subjects will begin by eating the soy bar first and half will begin by eating the placebo, and the way that subjects are assigned to each group is by chance. Subjects will not be told which bar they were receiving until the entire study has been completed by all subjects.

**Eligibility:** Based on the Menopausal Symptom Questionnaire and the Daily Symptoms Diary you are eligible to participate in the Intervention Group for this study. This is because you are experiencing more than five hot flashes each day.

**Study Requirements:** The length of this study is 7 months. During the first week of the study you will be asked to keep a three day food record. This requires that you write down all food and beverages consumed during a specified three day period and takes approximately 10-20 minutes each day. You will receive instructions on how to keep a food record, and will review the completed food record with the study coordinator. Also, during this week you will be asked to complete the daily symptoms diary. This will take a few minutes each day. Within one week of your screening/baseline blood sample another baseline blood sample (30ml or two Tablespoons) will be taken for measurement of hormones. On this morning you will also collect all of the urine from your first morning void. You will be provided with a bottle for the urine collection, a cooler and ice pack. The sample must be kept cold until you come to the clinic. At this visit you will be randomly assigned to either the soy supplement group or placebo.

**Phase I:** During Phase I you will consume two soy or placebo bars each day for three months. You will not be told which bar you are given until all the entire study has been completed by all participants. The study investigators and study coordinator will not know whether participants are consuming the soy or the placebo bar until the entire study has been completed by all participants. Each day you will be asked to record the number of hot flashes you have and indicate if both soy bars were eaten. You will record this information in the Study Log booklet. At the end of Phase I (Weeks 11-13) two blood samples (30 ml or two tablespoons/sample) will be taken on two days (within one week) and a urine collection will be done as before. During the last week of Phase I you will be asked to complete a Three Day Food Record, the Daily Symptoms Diary, and the Menopausal Symptoms Questionnaire. Finally, at the end of Phase I you will be asked to return any supplement bars that you did not eat.

**Phase II:** During this 4 week washout period you will not be consuming any supplement bars. You will be asked to keep track of the number of hot flashes using the Study Log and during the last week of Phase II you will be asked to complete a Three Day Food Record, the Daily

\_\_\_\_\_  
Participant's Initials

\_\_\_\_\_  
Date

### Consent Form 3 (Intervention)

Title: Menopausal Symptoms Study

Principal Investigator: Margo N. Woods, D.Sc.

Symptoms Diary and the Menopausal Symptoms Questionnaire.

**Phase III:** At the beginning of Phase III you will return to the clinic to review the food record with the study coordinator and to pick up your supplement bars for Phase III. If you were given the Soy Bar during Phase I you will consume the Placebo bar during Phase III, and if you were given the Placebo Bar during Phase III you will consume the Soy Bar during Phase II. You will not be told which bar you are given until all the entire study has been completed by all participants. The study investigators and study coordinator will not know whether participants are consuming the soy or the placebo bar until the entire study has been completed by all participants. You will consume two soy or placebo bars each day. Also, each day you will be asked to record the number of hot flashes you have and indicate if both soy bars were eaten. You will record this information in the Study Log booklet. At the end of Phase III (Weeks 11-13) two blood samples (30 ml or two Tablespoons/sample) will be taken on two days (approximately one week apart) and a urine collection will be done as before. Also during the last week of Phase III you will be asked to complete a Three Day Food Record, the Daily Symptoms Diary, and the Menopausal Symptoms Questionnaire. Finally, at the end of Phase III you will be asked to return any supplement bars that you did not eat.

**Dietary Supplement:** The soy and placebo bars to be used in this study were developed by Protein Technologies International, St. Louis, MO. The soy supplement bar and the placebo bar are made entirely from natural food products and all ingredients present in the bars are of dietary origin and quality. The placebo bar is indistinguishable from the soy product in appearance, texture and taste and has a similar nutrient content. The nutrient composition and ingredients used in the supplement bars will be shown to you by the study coordinator. You will have the opportunity to sample the bar prior to beginning the study.

**Laboratory Determinations:** Blood samples will be analyzed for a number of hormones including estrone, estradiol, estrone sulfate, androstenedione, and Follicle Stimulating Hormone. Urine samples will be analyzed for phytoestrogens and lignans..

**Blood Drawing:** The total amount of blood taken for this study will be 150 ml (approximately tablespoons) for this study.

**Risks:** There are no known risks associated with consuming the soy bar or placebo bar. There may be other hormone related physiological symptoms that we cannot anticipate. Blood drawing, in rare cases results in an infection and occasionally in a black and blue mark. Blood drawing when performed by somebody who has been specially trained and has experience in drawing blood decreases these risks. Because the soy bar and placebo contain milk products they may cause diarrhea or a stomach ache in individuals who can not digest or tolerate milk.

\_\_\_\_\_  
Participant's Initials

\_\_\_\_\_  
Date

3

**Consent Form 3 (Intervention)**

**Title:** Menopausal Symptoms Study

**Principal Investigator:** Margo N. Woods, D.Sc.

**Benefits:** The data obtained in this study may be of no direct benefit to the participant but may yield insight into the effects of diet on hormone metabolism and its possible role in the cause and development of breast cancer. Data from the blood analyses will be available to you. The soy supplement may alleviate some symptoms such as hot flashes experienced during menopause.

**Whom to Contact:** If you have any questions about the study or experience any problems or injury or illness during it, you should call one of the following persons:

	<u>Days</u>	<u>Evenings</u>
Dr. Margo Woods	617-636-0809	617-646-6059
Dr. Sherwood L. Gorbach	617-956-5811	617-636-5111 beeper # 1193

**Stipend:** You will be paid \$130 for participation in the study; \$50 at the end of Phase I and the remaining \$80 upon completion of the study. If you withdraw from the study before completing Phase I you will not receive any payment for your participation in the study. If you complete Phase I of the study but withdraw from the study before completing the study you will only be paid the \$50.00 for completing Phase I. There will be no cost to the participant for participating in this study.

It is the policy of the U.S. Army Medical Research, Development, Acquisition and Logistics Command (Provisional) (USAMRDALC) that data sheets are to be completed on all volunteers participating in research for entry into the USAMRDALC's Volunteer Registry Data Base. The information to be entered into the data base includes your name, address, social security number, study name and dates. The intent of the data base is twofold: first, to readily answer questions concerning an individual's participation in research sponsored by the USAMRDALC; and second, to ensure that the USAMRDALC can exercise its obligation to ensure that research volunteers are adequately warned (duty to warn) of risks and to provide new information as it becomes available. The information will be stored at USAMRDALC for a minimum of 75 years. The computer data base will be kept confidential and not released to anyone.

\_\_\_\_\_  
Participant's Initials

\_\_\_\_\_  
Date

Consent Form 3 (Intervention)

Title: Menopausal Symptoms Study

Principal Investigator: Margo N. Woods, D.Sc.

PARTICIPANT'S STATEMENT

I have read this consent form and have discussed with Dr. \_\_\_\_\_ or his representative the procedures described above. I have been given the opportunity to ask questions, which have been answered to my satisfaction. I understand that any questions I might have asked will be answered verbally or, If I prefer, with a written statement understand that I will be informed of any new findings developed during the course of this research study.

I understand that my participation in this study is voluntary. I understand that I may refuse to participate in this study. I also understand that if, for any reason, I wish to discontinue my participation in this study at any time, I will be free to do so, and this will have no effect on my future care or treatment by my physicians or this hospital.

I understand that I am authorized all necessary medical care for injury or illness which is the proximate result of my participation in this research. Other than medical care that may be provided (and the stipend specifically stated in this consent form) there is no compensation available for my participation in this research study, however, I understand that this is not a waiver or release of my legal rights.

If I have any questions concerning my rights as a research subject in this study, I may contact the Human Investigation Review Committee at 617-636-7512. This office is located at 35 Kneeland Street, 6th floor Boston, MA 02111.

I have been fully informed of the above-described study with its risks and benefits, and I hereby consent to the procedures set forth above. I have received a copy of this consent form.

I understand that as a participant in this study my identity and my medical records and data relating to this research study will be kept confidential, except as required by law, and except for inspections by the study sponsor, United States Army Medical Research, Development, Acquisition and Logistics (USAMRDAL) Command (Provisional).

\_\_\_\_\_  
Participant Signature

\_\_\_\_\_  
Date

\_\_\_\_\_  
Participant name (printed)

\_\_\_\_\_  
Address (street or PO Box, city, zip code)

Consent Form 3 (Intervention)

Title: Menopausal Symptoms Study

Principal Investigator: Margo N. Woods, D.Sc.

I have fully explained to \_\_\_\_\_ the nature and purpose of this above described study and the risks that are involved in its performance. I have answered all questions to the best of my ability.

\_\_\_\_\_  
Principal Investigator/Representative

\_\_\_\_\_  
Witness Signature

\_\_\_\_\_  
Witness Printed name

\_\_\_\_\_  
Date

APPROVED: 06/05/95  
VALID THROUGH: 12/13/94



#### **H. CONSENT FORM - SLOAN KETTERING**

Memorial Hospital  
1275 York Avenue  
New York, NY 10021

**PATIENT INFORMED CONSENT FOR CLINICAL RESEARCH**  
(Screening)

You are being asked to participate in a clinical research study. The doctors at Memorial Hospital study the nature of disease and attempt to develop improved methods of diagnosis and treatment. This is called clinical research. In order to decide whether or not you should agree to be part of this research study, you should understand enough about its risks and benefits to make an informed judgement. This process is known as informed consent.

This consent form gives detailed information about the research study which the doctor and nurse will discuss with you. Once you understand the study, you will be asked to sign the form if you wish to participate. You will have a copy to keep as a record.

This research study is called: The Effect of a Soy Dietary Supplement on Menopausal Symptoms and Hormone Levels in Women at High Risk of Breast Cancer

**PURPOSE OF THE RESEARCH:**

The purpose of this research study is to investigate the effect of dietary soy on hormones levels and menopausal symptoms in women at increased risk for breast cancer.

Menopausal symptoms have been associated with the decreased hormone levels that occur during menopause. Hormone replacement therapy (HRT) is given to approximately 30% of women in early menopause to alleviate some of the common symptoms experienced during menopause. While there are reported benefits of HRT on cardiovascular disease, osteoporosis, and menopausal symptoms there are concerns about the affect of HRT on breast cancer. Some studies have suggested that higher hormone levels may result in increased breast cancer risk.

Phytoestrogens are estrogen-like compounds found in plant products and high fiber foods including whole grains, legumes (especially soy) and some seeds. An increase in intake of soy products may contribute to the low incidence of breast and prostate cancer observed in Japanese women and men respectively. In addition, dietary soy has been shown to be inversely associated with breast cancer risk in Singapore. The relationship between soy and these cancers may be related to the phytoestrogens found in soy products, thus, it is possible that soy products may have an affect on hormone related, menopausal symptoms.

**Eligibility:** To determine eligibility for this study you will be asked to complete a medical history questionnaire. If you are eligible and agree to participate in this study a screening blood sample will be taken (20 ml -approximately 2 tablespoons) and routine blood chemistries will be analyzed. You will be asked to complete a menopausal symptoms questionnaire. This screening will take approximately 2 hours. Based on the results of the questionnaire you will be assigned to either the

\_\_\_\_\_  
Participant's Initial

\_\_\_\_\_  
Date

95-39

PERA  
SHEE  
8A

control group or the intervention group. If you are assigned to the control group only baseline data will be collected as described in Consent Form 2; the length of this study is 3 days.. If you are assigned to the intervention group you will be asked to participate in a 7 month dietary intervention study as described in Consent Form 3.

**Blood Drawing:** The total amount of blood to be taken for the routine blood chemistry analyses will be 20 ml. (approximately 1 1/2 tablespoons).

**Risks:** The only risks associated with this part of the study are those associated with blood drawing, which in rare cases results in an infection and occasionally in a black and blue mark. Blood drawing when performed by someone who has been specially trained and has experience in drawing blood decreases these risks.

**Benefits:** Although we hope that this research study will be of benefit to you, or that it will help others, we cannot say that it will help you directly. The data obtained in this study may yield insight into the effects of diet on hormone metabolism and its possible role in the cause and development of breast cancer.

Memorial Sloan-Kettering Cancer Center's Institutional Review Board is legally responsible for making sure that research with patients is appropriate and that the patient's rights and welfare are protected. It has reviewed this research study.

The clinicians in charge of this research study and the phone numbers where they can be reached are:

Dr. Ruby T. Senie 212-639-2373  
Dr. Alexandra Heerdt 212-639-2471  
Dr. Kimberly Van Zee 212-639-6997

If you need more information about this study before you decide to join, or at any other time, you may wish to contact one of these researchers. In the event you decide to participate, they should also be called if there are any side effects from the research study. You may also call Janice Levy (212-639-5804) for information about the consent process, patient's rights or research-related injury.

This study has been funded by the U.S. Army Medical Research, Development, Acquisition and Logistics Command (Provisional) (USAMRDALC). It is the policy of USAMRDALC that data sheets are to be completed on all volunteers participating in research for entry into the USAMRDALC's Volunteer Registry Data Base. The information to be entered into the data base includes your name, address, social security number, study name and dates. The intent of the data base is twofold: first, to readily answer questions concerning an individual's participation in research sponsored by the USAMRDALC; and second, to ensure that the USAMRDALC can exercise its obligation to ensure that research volunteers are adequately warned (duty to warn) of risks and to provide new information as it becomes available. The information will be stored at USAMRDALC for a minimum of 75 years. The computer data base will be kept confidential and not released to anyone.

Participant's Initial

Date

95-39

## PATIENT INFORMED CONSENT FOR CLINICAL RESEARCH PARTICIPANT'S

### TITLE

The Effect of a Soy Dietary Supplement on Menopausal Symptoms and Hormone Levels in Women at High Risk of Breast Cancer.

### PURPOSE

The purpose of this study is to investigate the effect of dietary soy on hormones levels and menopausal symptoms in women at increased risk for breast cancer.

### STATEMENT OF RESEARCH TEAM MEMBER OBTAINING INFORMED CONSENT:

I have fully explained this research study to the patient \_\_\_\_\_.  
\_\_\_\_\_. In my judgement, and the patient's, there was sufficient access to information, including risks and benefits, to make an informed decision.

\_\_\_\_\_  
Date

\_\_\_\_\_  
Signature of Research Team Member

\_\_\_\_\_  
Name of Research Team member

### PATIENT'S STATEMENT

I have read the description of the clinical research study or have had it translated into language I understand. I have also discussed the study with my doctor to my satisfaction. I understand that my participation is voluntary. I know enough about the purpose, methods, risks and benefits of the research study to judge that I want to take part in it.

\_\_\_\_\_  
Chart Number

\_\_\_\_\_  
Patient's Signature

\_\_\_\_\_  
Patient's Name - Print

\_\_\_\_\_  
Date

\_\_\_\_\_  
Participant's Initial

\_\_\_\_\_  
Date

95-39

Memorial Hospital  
1275 York Avenue  
New York, NY 10021

**PATIENT INFORMED CONSENT FOR CLINICAL RESEARCH  
(Intervention)**

You are being asked to participate in a clinical research study. The doctors at Memorial Hospital study the nature of disease and attempt to develop improved methods of diagnosis and treatment. This is called clinical research. In order to decide whether or not you should agree to be part of this research study, you should understand enough about its risks and benefits to make an informed judgement. This process is known as informed consent.

This consent form gives detailed information about the research study which the doctor and nurse will discuss with you. Once you understand the study, you will be asked to sign the form if you wish to participate. You will have a copy to keep as a record.

This research study is called: The Effect of a Soy Dietary Supplement on Menopausal Symptoms and Hormone Levels in Women at High Risk of Breast Cancer.

The following information will describe the study and your role as a participants. Members of the research team will answer any questions you may have about this form and about the study. Please read this carefully and do not hesitate to ask anything about the information provided below.

Menopausal symptoms such as hot flashes and night sweats have been associated with the decreased hormone levels that occur during menopause. Hormone replacement therapy (HRT) is given to approximately 30% of women in early menopause to alleviate some of the common symptoms experienced during menopause. While there are reported benefits of HRT on cardiovascular disease, osteoporosis, and menopausal symptoms there are concerns about the effect of HRT on breast cancer. Some studies have suggested that higher hormone levels may result in increased breast cancer risk.

Phytoestrogens are estrogen-like compounds found in plant products and high fiber foods including whole grains, legumes (especially soy) and some seeds. An increase in intake of soy products may contribute to the low incidence of breast and prostate cancer observed in Japanese women and men respectively. In addition, dietary soy has been shown to be inversely associated with breast cancer risk in Singapore. The relationship between soy and these cancers may be related to the phytoestrogens found in soy products, thus, it is possible that soy products may have an affect on hormone related, menopausal symptoms.

Purpose of the Study

The purpose of this study is to investigate the effect of dietary soy on hormones levels and menopausal symptoms in women at increased risk for breast cancer.

\_\_\_\_\_  
Participant's Initial

\_\_\_\_\_  
Date

95-39

1

PERM  
SHEET  
8A

### Description of Study Procedures

This 7 month dietary intervention study will use a random cross-over design to determine the effect of a **soy dietary supplement** on menopausal symptoms and endogenous hormones.

Based on the Menopausal Symptom Questionnaire you are eligible to participate in the Intervention Group for this study. This is because you are experiencing  $\geq 5$  hot flashes during daytime hours and/or  $\geq 5$  night sweats per week.

At baseline blood and urine collections will be done. Blood samples will be collected on two consecutive days (about 2 tablespoons or 30 ml each day) and a urine specimen will be collected. At the start of the study, women will be randomly assigned to either the soy supplement group or placebo group for three months. Subjects will consume two soy or placebo bars each day. At the end of the first three months blood and urine collections will be done as before. During the fourth month all study participants will consume placebo bars. During the remaining three months of the study women who were given the soy bar will be switched to the placebo bar and women who were given the placebo will be switched to the soy bar. At the end of the study blood and urine data will be collected as before.

Dietary data will be collected at baseline, and again at the end of three months and at the end of the study. At baseline a food frequency questionnaire (FFQ) will be completed; this takes approximately 20 minutes. A three day food record will be kept at baseline, and again during Phase I and Phase II. This requires that you write down all food and beverages consumed during a three day period. This takes approximately 10-20 minutes each day. You will receive instructions on how to keep a food record, and will be asked to review the completed food record with the study nutritionist. Throughout the study you will be asked to keep a daily diary of menopausal symptoms (hot flashes/night sweats).

### Soy Dietary Supplement

The soy bar to be used in this study were developed by Scientific Hospital Supplies, Liverpool, UK and followed guidelines to develop a nutritional, high protein breakfast bar, made from soy.

Soy Bar Ingredients: soy extract (10 gm), linseed (1 gm), rolled oats, rice crispies, dried fruit, sugar syrup and dried milk.

Placebo Bar Ingredients: casein extract, corn oil, rolled oats, rice crispies, dried fruit, sugar syrup and dried milk.

The soy bar and placebo bar have the following nutrient content:

	<u>Soy</u>	<u>Placebo</u>
Calories (k cal)	130	120
Fat (gm)	4.2	4.0
Protein (gm)	6.5	4.0
Carbohydrate (gm)	17	17.0
Fiber (gm)	6.0	1.0

Participant's Initial

Date

95-39

All ingredients present in the bars are of dietary origin and quality. The bar is similar to toffee with has a crunchy covering. The product was found to be very desirable in taste tests. The placebo bar, made from is indistinguishable from the soy product in appearance, texture and taste and has a similar nutrient content. The soy supplement bar and the placebo bar are made entirely from natural food products.

Blood samples will be analyzed for a number of hormones including estrone, estradiol, estrone sulfate, androstenedione, and follicle stimulating hormone. Urine samples will be analyzed for phytoestrogens and lignans.

The total amount of blood taken will be about 10 tablespoons (180 ml) for this study.

#### Stipend

You will be compensated \$130 for participation in the study; \$50 at the end of Phase I and the remaining \$80 at the end of the study.

#### Termination of Study

If you are unable to comply with the scheduled sequence for consumption of the dietary supplement and specimen collection, it may not be possible for you to continue in the study.

#### Side Effects

There are no known risks associated with consuming the soy bar or placebo bar.

Blood drawing by venipuncture, in rare cases results in an infection and occasionally in a black and blue mark. Blood drawing performed by an experienced phlebotomist decreases these risks. If you are injured as a result of your participation in this research study, emergency care, hospitalization and outpatient care will be made available by the hospital and billed to you as part of your medical expenses. No money will be provided by the hospital as compensation for research-related injury.

If you are injured as a result of your participation in this research study, emergency care, hospitalization and outpatient care will be made available by the hospital and billed to you as part of your medical expenses. No money will be provided by the hospital as compensation for research-related injury.

#### Benefits

The data obtained in this study may be of no direct benefit to the participant but may yield insight into the effects of diet on hormone metabolism and its possible role in the cause of breast cancer. Data from the blood analyses will be available to you. The soy supplement may alleviate some symptoms (hot flashes/night sweats) experienced during menopause.

#### Financial Costs

There will be no charge for the analysis of urine specimens and bloods drawn for this study.

\_\_\_\_\_  
Participant's Initial

\_\_\_\_\_  
Date

95-39

## Privacy

Your research and medical records are confidential. Your name or any other personal identifying information will not be used in any reports or publications resulting from the study. The Food and Drug Administration or other authorized agencies may inspect your records.

## Right to refuse or withdraw

The choice to enter, or not enter, this study is yours. You are in a position to make a decision if you understand what has been explained and what you have read about the research. You may decide not to participate or you may wish to discontinue your participation in this study at any time. Either decision will have no effect on your future care or treatment by physicians of this hospital.

Compensation for illness or injury: In the event of a physical illness or injury resulting from your participation in this research study, no monetary compensation will be made, but any emergency treatment that may be necessary will be made available to you as part of your care.

Memorial Sloan-Kettering Cancer Center's Institutional Review Board is legally responsible for making sure that research with patients is appropriate and that the patient's rights and welfare are protected. It has reviewed this research study.

The clinicians in charge of this research study and the phone numbers where they can be reached are:

Dr. Ruby T. Senie	212-639-2373
Dr. Alexandra Heerdt	212-639-2471
Dr. Kimberly Van Zee	212-639-6997

If you need more information about this study before you decide to join, or at any other time, you may wish to contact one of these researchers. In the event you decide to participate, they should also be called if there are any side effects from the research study. You may also call Janice Levy (212-639-5804) for information about the consent process, patient's rights or research-related injury.

This study has been funded by the U.S. Army Medical Research, Development, Acquisition and Logistics Command (Provisional) (USAMRDALC). It is the policy of USAMRDALC that data sheets are to be completed on all volunteers participating in research for entry into the USAMRDALC's Volunteer Registry Data Base. The information to be entered into the data base includes your name, address, social security number, study name and dates. The intent of the data base is twofold: first, to readily answer questions concerning an individual's participation in research sponsored by the USAMRDALC; and second, to ensure that the USAMRDALC can exercise its obligation to ensure that research volunteers are adequately warned (duty to warn) of risks and to provide new information as it becomes available. The information will be stored at USAMRDALC for a minimum of 75 years. The computer data base will be kept confidential and not released to anyone.

\_\_\_\_\_  
Participant's Initial

\_\_\_\_\_  
Date

95-39



**PATIENT INFORMED CONSENT FOR CLINICAL RESEARCH PARTICIPANT'S**

**TITLE**

The Effect of a Soy Dietary Supplement on Menopausal Symptoms and Hormone Levels in Women at High Risk of Breast Cancer.

**PURPOSE**

The purpose of this study is to investigate the effect of dietary soy on hormones levels and menopausal symptoms in women at increased risk for breast cancer.

**STATEMENT OF RESEARCH TEAM MEMBER OBTAINING INFORMED CONSENT:**

I have fully explained this research study to the patient \_\_\_\_\_. In my judgement, and the patient's, there was sufficient access to information, including risks and benefits, to make an informed decision.

\_\_\_\_\_  
Date

\_\_\_\_\_  
Signature of Research Team Member

\_\_\_\_\_  
Name of Research Team member

**PATIENT'S STATEMENT**

I have read the description of the clinical research study or have had it translated into language I understand. I have also discussed the study with my doctor to my satisfaction. I understand that my participation is voluntary. I know enough about the purpose, methods, risks and benefits of the research study to judge that I want to take part in it.

\_\_\_\_\_  
Chart Number

\_\_\_\_\_  
Patient's Signature

\_\_\_\_\_  
Patient's Name - Print

\_\_\_\_\_  
Date

March 1995

Memorial Hospital  
1275 York Avenue  
New York, NY 10021

**PATIENT INFORMED CONSENT FOR CLINICAL RESEARCH**  
**(Control)**

You are being asked to participate in a clinical research study. The doctors at Memorial Hospital study the nature of disease and attempt to develop improved methods of diagnosis and treatment. This is called clinical research. In order to decide whether or not you should agree to be part of this research study, you should understand enough about its risks and benefits to make an informed judgement. This process is known as informed consent.

This consent form gives detailed information about the research study which the doctor and nurse will discuss with you. Once you understand the study, you will be asked to sign the form if you wish to participate. You will have a copy to keep as a record.

This research study is called: The Effect of a Soy Dietary Supplement on Menopausal Symptoms and Hormone Levels in Women at High Risk of Breast Cancer.

The following information will describe the study and your role as a participants. Members of the research team will answer any questions you may have about this form and about the study. Please read this carefully and do not hesitate to ask anything about the information provided below.

Menopausal symptoms such as hot flashes and night sweats have been associated with the decreased hormone levels that occur during menopause. Hormone replacement therapy (HRT) is given to approximately 30% of women in early menopause to alleviate some of the common symptoms experienced during menopause. While there are reported benefits of HRT on cardiovascular disease, osteoporosis, and menopausal symptoms there are concerns about the effect of HRT on breast cancer. Some studies have suggested that higher hormone levels may result in increased breast cancer risk.

Phytoestrogens are estrogen-like compounds found in plant products and high fiber foods including whole grains, legumes (especially soy) and some seeds. An increase in intake of soy products may contribute to the low incidence of breast and prostate cancer observed in Japanese women and men respectively. In addition, dietary soy has been shown to be inversely associated with breast cancer risk in Singapore. The relationship between soy and these cancers may be related to the phytoestrogens found in soy products, thus, it is possible that soy products may have an affect on hormone related, menopausal symptoms.

Purpose of the Study

The purpose of this study is to investigate the effect of dietary soy on hormones levels and menopausal symptoms in women at increased risk for breast cancer.

\_\_\_\_\_  
Participant's Initial

\_\_\_\_\_  
Date

95-39

1

PERA  
SHEE  
8A

## Description of Study Procedures

Based on the Menopausal Symptom Questionnaire you are eligible to participate in the Control Group for this study. This is because you are experiencing low levels of menopausal symptoms( <2 hot flashes during daytime hours or < 1 incidence of night sweats per week) or you have no menopausal symptoms. The term "Control Group" is used because the purpose of your participation as a control subject is to collect data (hormone levels in blood and urinary phytoestrogens) in order to establish baseline values in postmenopausal women with low or no menopausal symptoms. These baseline values will be compared with values of women who are experiencing frequent menopausal symptoms.

The length of the study for women in the Control Group is 3 days. Blood samples will be collected on two consecutive days (about 2 tablespoons or 30 ml each day) for hormone measurements. And during one day a 24-hour urine collection will be done. This requires that all urine voided during the entire 24 hours must be collected. You will also keep a daily diary of symptoms (hot flashes and/or night sweats) during these 3 days. In addition, dietary intake data will be collected using a food frequency questionnaire and a three day food record.

The total amount of blood taken will be about 4 tablespoons (60 ml) for this study.

Stipend You will be compensated \$20 for your participation at the completion of the study.

### Side Effects

Blood drawing by venipuncture, in rare cases results in an infection and occasionally in a black and blue mark. Blood drawing performed by an experienced phlebotomist decreases these risks. If you are injured as a result of your participation in this research study, emergency care, hospitalization and outpatient care will be made available by the hospital and billed to you as part of your medical expenses. No money will be provided by the hospital as compensation for research-related injury.

### Benefits

The data obtained in this study may be of no direct benefit to the participant but may yield insight into the effects of diet on hormone metabolism and its possible role in the cause of breast cancer. Data from the blood analyses will be available to you. The soy supplement may alleviate some symptoms (hot flashes/night sweats) experienced during menopause.

### Financial Costs

There will be no charge for the analysis of urine specimens and bloods drawn for this study.

### Privacy

Your research and medical records are confidential. Your name or any other personal identifying information will not be used in any reports or publications resulting from the study. The Food and Drug Administration or other authorized agencies may inspect your records.

\_\_\_\_\_  
Participant's Initial

\_\_\_\_\_  
Date

95-39

Right to refuse or withdraw

The choice to enter, or not enter, this study is yours. You are in a position to make a decision if you understand what has been explained and what you have read about the research. You may decide not to participate or you may wish to discontinue your participation in this study at any time. Either decision will have no effect on your future care or treatment by physicians of this hospital.

Compensation for illness or injury: In the event of a physical illness or injury resulting from your participation in this research study, no monetary compensation will be made, but any emergency treatment that may be necessary will be made available to you as part of your care.

Memorial Sloan-Kettering Cancer Center's Institutional Review Board is legally responsible for making sure that research with patients is appropriate and that the patient's rights and welfare are protected. It has reviewed this research study.

The clinicians in charge of this research study and the phone numbers where they can be reached are:

Dr. Ruby T. Senie	212-639-2373
Dr. Alexandra Heerd	212-639-2471
Dr. Kimberly Van Zee	212-639-6997

If you need more information about this study before you decide to join, or at any other time, you may wish to contact one of these researchers. In the event you decide to participate, they should also be called if there are any side effects from the research study. You may also call Janice Levy (212-639-5804) for information about the consent process, patient's rights or research-related injury.

This study has been funded by the U.S. Army Medical Research, Development, Acquisition and Logistics Command (Provisional) (USAMRDALC). It is the policy of USAMRDALC that data sheets are to be completed on all volunteers participating in research for entry into the USAMRDALC's Volunteer Registry Data Base. The information to be entered into the data base includes your name, address, social security number, study name and dates. The intent of the data base is twofold: first, to readily answer questions concerning an individual's participation in research sponsored by the USAMRDALC; and second, to ensure that the USAMRDALC can exercise its obligation to ensure that research volunteers are adequately warned (duty to warn) of risks and to provide new information as it becomes available. The information will be stored at USAMRDALC for a minimum of 75 years. The computer data base will be kept confidential and not released to anyone.

\_\_\_\_\_  
Participant's Initial

\_\_\_\_\_  
Date

95-39

## PATIENT INFORMED CONSENT FOR CLINICAL RESEARCH

### TITLE

The Effect of a Soy Dietary Supplement on Menopausal Symptoms and Hormone Levels in Women at High Risk of Breast Cancer.

### PURPOSE

The purpose of this study is to investigate the effect of dietary soy on hormones levels and menopausal symptoms in women at increased risk for breast cancer.

### STATEMENT OF RESEARCH TEAM MEMBER OBTAINING INFORMED CONSENT:

I have fully explained this research study to the patient \_\_\_\_\_.  
\_\_\_\_\_. In my judgement, and the patient's, there was sufficient access to information, including risks and benefits, to make an informed decision.

\_\_\_\_\_  
Date

\_\_\_\_\_  
Signature of Research Team Member

\_\_\_\_\_  
Name of Research Team member

### PATIENT'S STATEMENT

I have read the description of the clinical research study or have had it translated into language I understand. I have also discussed the study with my doctor to my satisfaction. I understand that my participation is voluntary. I know enough about the purpose, methods, risks and benefits of the research study to judge that I want to take part in it.

\_\_\_\_\_  
Chart Number

\_\_\_\_\_  
Patient's Signature

\_\_\_\_\_  
Patient's Name - Print

\_\_\_\_\_  
Date

## **I. RECRUITMENT MATERIAL - TUFTS**

Date

Dear Ms.

Because you are a patient at the Breast Health Center at New England Medical Center Hospital we are writing to tell you about a study we are currently conducting on menopausal symptoms. This study is investigating the relationship between diet, hormones and menopausal symptoms.

You are eligible for the study if you are:

- ✓ post-menopausal
- ✓ not taking hormones
- ✓ not smoking
- ✓ at increased risk of breast cancer

The study is not very demanding but may ask you to:

- ✓ collect dietary data
- ✓ record menopausal symptom data
- ✓ provide blood samples for hormone determinations
- ✓ eat a dietary supplement bar twice a day

Enclosed is a flyer which provides more detailed information about the Menopausal Symptoms Study. If you are interested or would like more information about the study please call the Menopausal Symptoms Study Recruiting Line 617-636-6176. Ann LaBrode or Emily Potts will return your call and answer your questions.

Sincerely,

Susan Sajer, MD  
Breast Health Center

Margo Woods, D.Sc.  
Principal Investigator  
Tufts University School of Medicine



**MENPOP**



## **MENOPAUSAL SYMPTOMS STUDY**

We are looking at the relationship between diet, hormones and menopausal symptoms such as hot flashes. You may be eligible if you are:

- ✓ Menopausal
- ✓ 45-58 Years Old
- ✓ not taking hormones
- ✓ not smoking

---

For more information call 617-636-6176  
Nutrition Unit, Tufts University School of Medicine

We are interested in having you join our study investigating the relationship between diet, hormones, and menopausal symptoms.

You may be eligible if you are:

- ✓ menopausal
- ✓ not taking hormones
- ✓ not smoking
- ✓ at increased risk of breast cancer

We may ask you to:

- ✓ collect dietary data
- ✓ collect menopausal symptoms data
- ✓ provide blood for hormone determinations
- ✓ take a tasty dietary supplement bar twice a day

You may benefit by obtaining diet and hormone information and a decrease of menopausal symptoms is possible. A stipend of up to \$130 is available.

**If you are interested or would like more information about the Menopausal Symptoms Study, please call the Menopausal Symptoms Study Recruiting Line at 617-636-6176. A study representative will return your call.**



# **Menopausal Symptoms Study**

## **Tufts University School of Medicine**

**We are interested in having you join our study investigating the relationship between diet, hormones and menopausal symptoms such as hot flashes and night sweats**

**You may be eligible if you are:**

- ✓ **Post-menopausal**
- ✓ **Not taking hormones**
- ✓ **Not smoking**
- ✓ **Age 45-58**

**If you are interested or would like more information about the Menopausal Symptoms Study, please call the Study Recruiting Line at 617-636-6176.**

### **MENOPAUSAL SYMPTOMS STUDY**

We are looking at the relationship between diet, hormones and menopausal symptoms such as hot flashes. You may be eligible if you are:

- ✓ Postmenopausal
- ✓ 45-58 Years old
- ✓ Not taking hormones
- ✓ Not smoking

**For more information call 617-636-6176  
Nutrition Unit, Tufts University School of Medicine**

TELEPHONE SCREENING QUESTIONNAIRE  
- MENOPAUSAL SYMPTOMS STUDY (MSS)

Complete entire questionnaire.

ELIGIBLE \_\_\_\_\_

INELIGIBLE \_\_\_\_\_

WILL BE ELIGIBLE \_\_\_\_\_

Name: \_\_\_\_\_

Date \_\_\_\_\_

Address: \_\_\_\_\_  
\_\_\_\_\_

Telephone: home \_\_\_\_\_ work \_\_\_\_\_

Are you currently a smoker? ☐ No ☐ Yes

Age \_\_\_\_\_ (48-58 eligible) Date of Birth \_\_\_\_\_

1. Are you post menopausal? ☐ No ☐ Yes, If Yes, was it:

\_\_\_\_\_ Natural

\_\_\_\_\_ Surgical, Were ovaries removed?

\_\_\_\_\_ No ☐ Don't Know ☐ Yes If yes,

\_\_\_\_\_ One, When \_\_\_\_\_

\_\_\_\_\_ Both When \_\_\_\_\_

2. When was your last menstrual period? Month \_\_\_\_\_ Year \_\_\_\_\_ if < 1 year, not eligible

3. Have you had any menstrual bleeding in the past 12 months? ☐ No ☐ Yes

If yes, was it only spotting, ☐ No ☐ Yes,

4. Are you currently taking any hormone medications? ☐ No ☐ Yes

5. Have you taken hormone medications in the past? ☐ No ☐ Yes

If yes, when did you stop taking them? \_\_\_\_\_ (< 6 months not eligible)

Hot flashes, flushes and night sweats are sudden episodes of feeling warm, flushing, and /or sweating.

6. Do you ever have hot flashes? ☐ No (Skip to Question 7) ☐ Yes

If yes, Do you have them during the day? ☐ No ☐ Yes

How often, \_\_\_\_\_/Day \_\_\_\_\_/Week

Do you have them at night? ☐ No ☐ Yes

How often, \_\_\_\_\_/Day \_\_\_\_\_/Week

7. Are you currently taking any prescription medications? ☐ No ☐ Yes

If yes, what are they? \_\_\_\_\_ Check medication  
\_\_\_\_\_ list to see if  
\_\_\_\_\_ patient still  
\_\_\_\_\_ qualifies

8. Risk factors for Breast Cancer: (Use in Boston Only)

A. Do you have any relatives who have had breast cancer? ☐ No ☐ Yes

If Yes, indicate:

Age of Diagnosis

\_\_\_\_\_ Mother \_\_\_\_\_

\_\_\_\_\_ Sister \_\_\_\_\_

\_\_\_\_\_ Daughter \_\_\_\_\_

\_\_\_\_\_ Other \_\_\_\_\_

B. Have you had a breast biopsy? ☐ No ☐ Yes, If Yes, how many? \_\_\_\_\_ (number)

When did you have the biopsies? \_\_\_\_\_ What were the results? Benign \_\_\_\_\_ Malignant \_\_\_\_\_

C. Have you had a breast biopsy diagnosed as atypical or proliferative breast disease? ☐ No ☐ Yes

### MSS Control Checklist

<b>ID.</b>	<b>SBVI CV1</b>	<b>CV2</b>
<b>Forms</b>		
Medical F3	<input type="checkbox"/> review	
Menopausal Sx F2	<input type="checkbox"/> review	
7 Day Sx Diary F5	<input type="checkbox"/> review	<input type="checkbox"/> review
Study Log F4		
Food frequency N2	<input type="checkbox"/> instruct	<input type="checkbox"/> review
3 Day Food Rec. N1	<input type="checkbox"/> instruct	<input type="checkbox"/> document
Consent Form S	<input type="checkbox"/> explain and sign	
<b>Blood</b>	<input type="checkbox"/> 40 ml	<input type="checkbox"/> 30 ml
<b>Urine</b>	<input type="checkbox"/> distribute kit	<input type="checkbox"/> Collect
<b>Height/Weight</b>	<input type="checkbox"/> Ht. <input type="checkbox"/> Wt.	<input type="checkbox"/> Wt.
<b>Schedule</b>	CV2	
<b>Calendar</b>	CV2 urine coll 3 Day Food Rec 7 Day Sx Diary	
<b>Give Ppt.</b>	Calendar urine coll kit 3 Day food rec 7 Day Sx Diary	\$20 payment

# MSS Intervention Checklist

	SBV1	BV2	V3	V4	IV5	FV6	FV7
<b>Forms</b>							
Medical F3	<input type="checkbox"/> review						
Menopausal Sx F2	<input type="checkbox"/> review		<input type="checkbox"/> fill out		<input type="checkbox"/> fill out		
7 Day Sx. Diary F5	<input type="checkbox"/> review <input type="checkbox"/> distribute	<input type="checkbox"/> review	<input type="checkbox"/> reinstruct <input type="checkbox"/> distribute	<input type="checkbox"/> review <input type="checkbox"/> distribute	<input type="checkbox"/> review	<input type="checkbox"/> distribute	<input type="checkbox"/> review
Study Log F4		<input type="checkbox"/> instruct	<input type="checkbox"/> review	<input type="checkbox"/> review	<input type="checkbox"/> review	<input type="checkbox"/> review	
Food Frequency N2	<input type="checkbox"/> instruct	<input type="checkbox"/> review					
3 Day Food Rec.N1	<input type="checkbox"/> instruct	<input type="checkbox"/> document	<input type="checkbox"/> reinstruct <input type="checkbox"/> distribute	<input type="checkbox"/> document <input type="checkbox"/> distribute	<input type="checkbox"/> document	<input type="checkbox"/> distribute	<input type="checkbox"/> document
Consent Form S	<input type="checkbox"/> explain/sign						
Supplement Bars		<input type="checkbox"/> 1 mo supply			<input type="checkbox"/> 1 mo supply		
Blood	<input type="checkbox"/> 40 ml	<input type="checkbox"/> 30 ml	<input type="checkbox"/> 30 ml	<input type="checkbox"/> 30 ml		<input type="checkbox"/> 30 ml	<input type="checkbox"/> 30 ml
Urine	<input type="checkbox"/> distribute kit	<input type="checkbox"/> collect sample	<input type="checkbox"/> distribute kit	<input type="checkbox"/> collect sample		<input type="checkbox"/> distribute kit	<input type="checkbox"/> collect sample
Height/Weight	<input type="checkbox"/> height <input type="checkbox"/> weight	<input type="checkbox"/> weight	<input type="checkbox"/> weight	<input type="checkbox"/> weight	<input type="checkbox"/> weight	<input type="checkbox"/> weight	<input type="checkbox"/> weight
Schedule	BV2	V3 and V4	confirm V4	IV5	FV6 and FV7	confirm FV7	
Calendar	BV2 7 day Sx. diary 3 day food rec urine collect	mail study log V3 and V4 3 day food rec 7 day Sx. diary urine coll	V4 3 day food rec 7 day Sx. diary urine coll	IV5 3 day food rec 7 day Sx. diary	FV6 and FV7 3 day food recs 7 Day Sx. diary Urine Coll Mail Study log	FV7 3 day food rec 7 day Sx diary Urine coll	
Give Ppt.	Calendar 7 day Sx. diary 3 day foodrec urine coll kit food frequency	Calendar Supp. Supply study logs mailers	Calendar 7 day sx diary urine coll kit 3 day food rec	Calendar 3 day food rec. 7 day sx diary \$50 payment	Calendar Supp Supply study log Mailers	Calendar 3 day food rec 7 day sx diary Urine coll kit	Complete Evaluation \$80 payment

**J. RECRUITMENT MATERIAL - SLOAN KETTERING**

**THE BREAST SERVICE  
DEPARTMENT OF SURGERY**

**Memorial Sloan-Kettering  
Cancer Center**

**Patrick Borgen, MD  
Chief, Breast Service**

**Hiram S. Cody, MD**


**Alexandra Heerdt, MD**

**Jeanne Petrek, MD**

**Ruby T. Senie, PhD**

**Kimberly J. Van Zee, MD**

**MENOPAUSAL SYMPTOMS STUDY  
212 639-2598**



**MENOPAUSAL  
SYMPTOMS  
STUDY**

**HORMONE LEVELS  
&  
SYMPTOMS**

**You may be interested if you are:**

- ▶ menopausal
- ▶ 45 to 60 years of age
- ▶ not taking hormones
- ▶ not smoking



**Memorial Sloan-Kettering Cancer Center  
205 East 64th Street  
New York, New York 10021**

**Breast Service  
Department of Surgery  
Menopausal Symptoms Study**

**212 639-2598**

**Memorial Sloan-Kettering Cancer Center  
Breast Service, Department of Surgery  
Menopausal Symptoms Study**

**212 639-2598**

## **WHAT IS THIS STUDY ABOUT?**

We are studying the relationship of hormone levels, food, and menopausal symptoms.

## **WHAT WILL I BE ASKED TO DO?**

Keep a food record

Record menopausal symptoms

Provide blood and urine for hormone analysis

Some women will be asked to eat a tasty snack twice a day

## **WILL THERE BE ANY COST TO ME?**

No, this study is funded by the Army Breast Cancer Research Program.

You will be given a small stipend to help cover parking and transportation costs.

## **HOW WILL I BENEFIT FROM THE STUDY ?**

You will learn more about your hormone levels and menopausal symptoms.

## **CAN I BE IN THE STUDY?**

We are interested in having you join our study if you fit the following description. Please call us at 212 639-2598 for more information.

\*No menstrual period during past 12 months

\*45 to 60 years of age

\*Non-smoker

\*Not taking hormones

\*Family history of breast cancer

\*No hysterectomy

FOR MORE INFORMATION  
PLEASE CALL  
PROJECT COORDINATOR

**212 639-2598**

June, 1995

Dear ,

Since you are a member of Memorial's Special Surveillance Breast Program, we would like to tell you about a study we are about to begin. Its purpose is to look at the relationship of hormone levels, menopausal symptoms, and nutrition.

If you can agree with each of the following statements you may be able to join this study:

- I have had no menstrual period during the past year
- My age is between 48 to 58
- I am not taking hormones
- A am non-smokers
- I have a family history of breast cancer

During the study you may be asked to keep a three day food record, bring in a urine specimen, have blood drawn for hormone levels, describe any hot flashes, and eat a tasty food supplement bar.

For participating in the study you will receive a small stipend to cover travel and parking expenses and will receive information on your individual hormone levels. We have received research support from the federal government for this study.

If you think you would like to be part of this study or would just like more information, please call Jane Fey, Project Coordinator of the Menopause Study at (212) 639-2598. Please leave a message and Jane will be glad to call you back to answer any of your questions.


Sincerely,

Alexandra Heerdt, M.D.

Kimberly Van Zee, M.D.




# Menopausal Symptom Study Assignment and Randomization



# Menopausal Symptom Study


## Assignment and Randomization

Memorial Sloan Kettering Cancer Center



# Menopausal Symptom Study

Random Assignment - Tufts & MSKCC



# CONTROLS

Visit 1

Visit 2

Consent Form
Med Hx
Food Fq-
Meno Sx
SBV1
Bld Drawn
Wt & Hgt
Urine cup
Green Diary
SBV1
Food Record-N1


2-7 days



Bld Drawn
First urine

→ To be returned after 7 days

# Dietary Supplement - Phase 1



# Dietary Supplement - Resting & Phase 2

VISIT 5

/ /

VISIT 6

/ /

VISIT 7

/ /

**3 Weeks**



**Send:**  
**Green Diary**  
**Food Record**

Meno Sx

Bld Drawn  
Wgt

Pink Log  
Dietary Bars

Urine Cup

Return:  
Green Diary  
Food Record

**11 Weeks**



**Phone  
& Mail  
Contact**

Bld Drawn  
Wgt  
Meno Sx

Urine Cup

Green Diary  
Food Record

**2 - 7  
Days**



Bld drawn  
First urine  
Wgt

Return:  
Green Diary  
Food Record

Mail Stipend

Menopausal  
Symptom Study  
7/95

**K. PROTEIN TECHNOLOGY, INTERNATIONAL (PTI) SUPPLEMENT BAR  
NUTRIENT CONTENT**

**TUFTS UNIVERSITY - BARS - First Production**

		<u>per serving/bar</u>	
		Uncoated 675HG 2656-18-2	Uncoated Placebo 2656-18-3
Serving	Units		
	g	56	56
Moisture	g	6.5	6.7
Fat	g	1.3	0.9
Protein	g	15.1	16.4
Ash	g	2.0	2.1
CHO (by diff)	g	31.1	29.9
Calories	Kcal	196	194
Ca	mg	711	497
Fe	mg	4.0	2.1
P	mg	502	304
Na	mg	168	106
Folic Acid	mcg	142	158
Pan Acid	mg	0.94	0.78
B6	mg	0.26	0.23
B2	mg	0.45	0.35
B1	mg	0.23	0.14
Vit A	IU	668	809
B12	meg	1.29	3.19
Vit C	mg	1.41	1.67
Vit D	IU	153	164